Access Equity Research

News

Virtual & In-person Roadshows / Conferences

Channelchek Premium. Access more at no cost. 

The site "channelcheck" is opened on the phone

Join the Premium Channelchek Investor Community. Your name, email, Zip / Postal and investor type is all it takes to open the door to research reports, favorites tracking, and virtual and in-person roadshows / conferences. Even exclusive investment opps.

Take it to the next level. It doesn’t cost a penny.

Click “Log In” to agree to Channelchek.com <a href="#">Terms of Use</a> and acknowledge that Channelchek.com <a href="#">Privacy Policy</a> applies to you.

Welcome to the NEW Channelchek Premium Investor Community

Informed investors make more money. And it’s all about timing. Get it when it happens.

Inbox Intel from Channelchek.

<figure class="wp-block-image aligncenter size-full"><img src="https://dashboard.channelchek.com/wp-content/uploads/2022/09/cocp-logo-pr-1.png" alt="" class="wp-image-49026"/></figure>



<a href="http://www.channelchek.com/company/cocp">Research, News, and Market Data on COCP</a>



DECEMBER 01, 2022



Affirms plans&nbsp;to report topline&nbsp;Phase 1 results in 2022 and&nbsp;to&nbsp;initiate&nbsp;Phase 2a&nbsp;influenza&nbsp;human challenge trial&nbsp;in 2023



BOTHELL, Wash., Dec. 01, 2022 (GLOBE NEWSWIRE) --&nbsp;Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that progress with&nbsp;CC-42344&nbsp;for the treatment of pandemic and seasonal influenza A from its Phase 1 study was presented today at the World Antiviral Congress 2022 underway in San Diego. The presentation, “Novel Broad-Spectrum Influenza A PB2 Inhibitor: Clinical Update,” was delivered by Cocrystal President and co-interim CEO Sam Lee, PhD and the slides are available&nbsp;<a href="https://www.globenewswire.com/Tracker?data=Y6RZcIZDbAYRuRKsIPPp4LxG2Xk3Muu1xPO4JRpuOhEIF2yc1KIRmFSzE-e_ZmoyYQaL2uqCelWA-OtlDubFfCryzuu0JV16NKjwQVt5k60=" target="_blank" rel="noreferrer noopener">here</a>.



“We appreciate the opportunity to present our antiviral drug discovery platform technology and favorable interim Phase 1 data,” said Dr. Lee. “Seasonal and pandemic influenza A continue to be major global health threats, especially given the potential for resistance against approved antivirals. Our presentation highlights potential clinical benefits for the treatment of pandemic influenza and the advantages of the oral influenza antiviral&nbsp;CC-42344&nbsp;drug, which targets the PB2 protein of the influenza polymerase complex. We believe this novel mechanism of action holds promise against all significant influenza A strains including bird flu, while also having a high barrier to resistance. Our assessment to date also indicates that&nbsp;CC-42344&nbsp;will have a strong synergistic effect when used with approved antivirals.”



In November 2022 Cocrystal reported that orally administered&nbsp;CC-42344&nbsp;showed a favorable safety profile in both the single- and multiple-ascending dose portions of the Phase 1 study. The Company is currently awaiting pharmacokinetic results from this study and plans to report topline results later this year.



About&nbsp;CC-42344 CC-42344&nbsp;is a novel PB2 inhibitor discovered using Cocrystal’s proprietary structure-based drug discovery platform technology.&nbsp;CC-42344&nbsp;targets the influenza polymerase, an essential replication enzyme with several highly conserved regions common to multiple influenza strains.&nbsp;In vitro&nbsp;testing showed&nbsp;CC-42344’s excellent antiviral activity against influenza A strains, including pandemic and seasonal strains, as well as against strains resistant to Tamiflu®&nbsp;and Xofluza®.



About Cocrystal Pharma, Inc. Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit&nbsp;<a href="https://www.globenewswire.com/Tracker?data=arx4ie_rfUn0fk5TJwmpzsISncR856-F-KuEUwwFMT7Bk8ueCGiuwDU1zLB58hWnd_EtD2Kb336V8AFpWhw663OC1zBVG8P7hGDoUtLKCao=" target="_blank" rel="noreferrer noopener">www.cocrystalpharma.com</a>.



Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the potential clinical benefits of CC-42344, including its prospective efficacy against all influenza A strains, high barrier to resistance and synergistic effects with approved antivirals, and our plans to report topline results of the Phase 1 study by the end of 2022. The words "believe," "may," "estimate," "continue," "anticipate," "intend," "should," "plan," "could," "target," "potential," "is likely," "will," "expect" and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events. Some or all of the events anticipated by these forward-looking statements may not occur. Important factors that could cause actual results to differ from those in the forward-looking statements include, but are not limited to, the risks and uncertainties arising from any future impact of COVID-19 (including long-term or pervasive effects of the virus), inflation, interest rate increases and the war in Ukraine on the U.K. and global economy and on our Company, including supply chain disruptions and our continued ability to proceed with our programs, including our influenza A program, the ability of the contract research organization to recruit patients into clinical trials, the results of future preclinical and clinical studies, and general risks arising from clinical trials. Further information on our risk factors is contained in our filings with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2021. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.



Investor Contact: LHA Investor Relations Jody Cain 310-691-7100 <a href="https://www.globenewswire.com/Tracker?data=-crut1EGNA4MpTsnHRm-7tfLtPQdqRrr_CI1atZewS_GjY1E4S8zXZldZ3cEu_-kyNPxfL7pgEwCckcdLC4rsQ==" target="_blank" rel="noreferrer noopener">jcain@lhai.com</a>&nbsp;



Media Contact: JQA Partners Jules Abraham 917-885-7378 <a href="https://www.globenewswire.com/Tracker?data=L9U1PXvkznfTqVNwoavlqEkvaVsQhWZJzTO3dHMjhCxd_R8Nk_WbsJVpkppmPAbb5df35ofgl5F1jHOuiaGBKX46a0P6Qn7u59xYWcQuFOk=" target="_blank" rel="noreferrer noopener">Jabraham@jqapartners.com</a>



+# # #



<a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/ba04b6e2-72b0-4133-a46c-65bef5061ea4"></a>



Source: Cocrystal Pharma, Inc.



Released December 1, 2022

<div class="wp-block-image">
<figure class="aligncenter size-full"><img decoding="async" loading="lazy" width="411" height="75" src="https://dashboard.channelchek.com/wp-content/uploads/2022/09/cocp-logo-pr-1.png" alt="" class="wp-image-49026" srcset="https://dashboard.channelchek.com/wp-content/uploads/2022/09/cocp-logo-pr-1.png 411w, https://dashboard.channelchek.com/wp-content/uploads/2022/09/cocp-logo-pr-1-300x55.png 300w" sizes="(max-width: 411px) 100vw, 411px" /></figure></div>


<a href="http://www.channelchek.com/company/cocp">Research, News, and Market Data on COCP</a>



DECEMBER 01, 2022



Affirms plans&nbsp;to report topline&nbsp;Phase 1 results in 2022 and&nbsp;to&nbsp;initiate&nbsp;Phase 2a&nbsp;influenza&nbsp;human challenge trial&nbsp;in 2023



BOTHELL, Wash., Dec. 01, 2022 (GLOBE NEWSWIRE) &#8212;&nbsp;Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that progress with&nbsp;CC-42344&nbsp;for the treatment of pandemic and seasonal influenza A from its Phase 1 study was presented today at the World Antiviral Congress 2022 underway in San Diego. The presentation, “Novel Broad-Spectrum Influenza A PB2 Inhibitor: Clinical Update,” was delivered by Cocrystal President and co-interim CEO Sam Lee, PhD and the slides are available&nbsp;<a href="https://www.globenewswire.com/Tracker?data=Y6RZcIZDbAYRuRKsIPPp4LxG2Xk3Muu1xPO4JRpuOhEIF2yc1KIRmFSzE-e_ZmoyYQaL2uqCelWA-OtlDubFfCryzuu0JV16NKjwQVt5k60=" target="_blank" rel="noreferrer noopener">here</a>.



“We appreciate the opportunity to present our antiviral drug discovery platform technology and favorable interim Phase 1 data,” said Dr. Lee. “Seasonal and pandemic influenza A continue to be major global health threats, especially given the potential for resistance against approved antivirals. Our presentation highlights potential clinical benefits for the treatment of pandemic influenza and the advantages of the oral influenza antiviral&nbsp;CC-42344&nbsp;drug, which targets the PB2 protein of the influenza polymerase complex. We believe this novel mechanism of action holds promise against all significant influenza A strains including bird flu, while also having a high barrier to resistance. Our assessment to date also indicates that&nbsp;CC-42344&nbsp;will have a strong synergistic effect when used with approved antivirals.”



In November 2022 Cocrystal reported that orally administered&nbsp;CC-42344&nbsp;showed a favorable safety profile in both the single- and multiple-ascending dose portions of the Phase 1 study. The Company is currently awaiting pharmacokinetic results from this study and plans to report topline results later this year.



About&nbsp;CC-42344 CC-42344&nbsp;is a novel PB2 inhibitor discovered using Cocrystal’s proprietary structure-based drug discovery platform technology.&nbsp;CC-42344&nbsp;targets the influenza polymerase, an essential replication enzyme with several highly conserved regions common to multiple influenza strains.&nbsp;In vitro&nbsp;testing showed&nbsp;CC-42344’s excellent antiviral activity against influenza A strains, including pandemic and seasonal strains, as well as against strains resistant to Tamiflu®&nbsp;and Xofluza®.



About Cocrystal Pharma, Inc. Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit&nbsp;<a href="https://www.globenewswire.com/Tracker?data=arx4ie_rfUn0fk5TJwmpzsISncR856-F-KuEUwwFMT7Bk8ueCGiuwDU1zLB58hWnd_EtD2Kb336V8AFpWhw663OC1zBVG8P7hGDoUtLKCao=" target="_blank" rel="noreferrer noopener">www.cocrystalpharma.com</a>.



Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the potential clinical benefits of CC-42344, including its prospective efficacy against all influenza A strains, high barrier to resistance and synergistic effects with approved antivirals, and our plans to report topline results of the Phase 1 study by the end of 2022. The words &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;should,&#8221; &#8220;plan,&#8221; &#8220;could,&#8221; &#8220;target,&#8221; &#8220;potential,&#8221; &#8220;is likely,&#8221; &#8220;will,&#8221; &#8220;expect&#8221; and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events. Some or all of the events anticipated by these forward-looking statements may not occur. Important factors that could cause actual results to differ from those in the forward-looking statements include, but are not limited to, the risks and uncertainties arising from any future impact of COVID-19 (including long-term or pervasive effects of the virus), inflation, interest rate increases and the war in Ukraine on the U.K. and global economy and on our Company, including supply chain disruptions and our continued ability to proceed with our programs, including our influenza A program, the ability of the contract research organization to recruit patients into clinical trials, the results of future preclinical and clinical studies, and general risks arising from clinical trials. Further information on our risk factors is contained in our filings with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2021. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.



Investor Contact: LHA Investor Relations Jody Cain 310-691-7100 <a href="https://www.globenewswire.com/Tracker?data=-crut1EGNA4MpTsnHRm-7tfLtPQdqRrr_CI1atZewS_GjY1E4S8zXZldZ3cEu_-kyNPxfL7pgEwCckcdLC4rsQ==" target="_blank" rel="noreferrer noopener">jcain@lhai.com</a>&nbsp;



Media Contact: JQA Partners Jules Abraham 917-885-7378 <a href="https://www.globenewswire.com/Tracker?data=L9U1PXvkznfTqVNwoavlqEkvaVsQhWZJzTO3dHMjhCxd_R8Nk_WbsJVpkppmPAbb5df35ofgl5F1jHOuiaGBKX46a0P6Qn7u59xYWcQuFOk=" target="_blank" rel="noreferrer noopener">Jabraham@jqapartners.com</a>



+# # #



<a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/ba04b6e2-72b0-4133-a46c-65bef5061ea4"></a>



Source: Cocrystal Pharma, Inc.



Released December 1, 2022

Research, News, and Market Data on COCP



DECEMBER 01, 2022



Affirms plans&nbsp;to report topline&nbsp;Phase 1 results in 2022 and&nbsp;to&nbsp;initiate&nbsp;Phase 2a&nbsp;influenza&nbsp;human challenge trial&nbsp;in 2023



BOTHELL, Wash., Dec. 01, 2022 (GLOBE NEWSWIRE) &#8212;&nbsp;Cocrystal Pharma, Inc. (Nasdaq: COCP) announces that progress with&nbsp;CC-42344&nbsp;for the treatment of pandemic and seasonal influenza A from its Phase 1 study was presented today at the World Antiviral Congress 2022 underway in San Diego. The presentation, “Novel Broad-Spectrum Influenza A PB2 Inhibitor: Clinical Update,” was delivered by Cocrystal President and co-interim CEO Sam Lee, PhD and the slides are available&nbsp;here.



“We appreciate the opportunity to present our antiviral drug discovery platform technology and favorable interim Phase 1 data,” said Dr. Lee. “Seasonal and pandemic influenza A continue to be major global health threats, especially given the potential for resistance against approved antivirals. Our presentation highlights potential clinical benefits for the treatment of pandemic influenza and the advantages of the oral influenza antiviral&nbsp;CC-42344&nbsp;drug, which targets the PB2 protein of the influenza polymerase complex. We believe this novel mechanism of action holds promise against all significant influenza A strains including bird flu, while also having a high barrier to resistance. Our assessment to date also indicates that&nbsp;CC-42344&nbsp;will have a strong synergistic effect when used with approved antivirals.”



In November 2022 Cocrystal reported that orally administered&nbsp;CC-42344&nbsp;showed a favorable safety profile in both the single- and multiple-ascending dose portions of the Phase 1 study. The Company is currently awaiting pharmacokinetic results from this study and plans to report topline results later this year.



About&nbsp;CC-42344CC-42344&nbsp;is a novel PB2 inhibitor discovered using Cocrystal’s proprietary structure-based drug discovery platform technology.&nbsp;CC-42344&nbsp;targets the influenza polymerase, an essential replication enzyme with several highly conserved regions common to multiple influenza strains.&nbsp;In vitro&nbsp;testing showed&nbsp;CC-42344’s excellent antiviral activity against influenza A strains, including pandemic and seasonal strains, as well as against strains resistant to Tamiflu®&nbsp;and Xofluza®.



About Cocrystal Pharma, Inc.Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit&nbsp;www.cocrystalpharma.com.



Cautionary Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the potential clinical benefits of CC-42344, including its prospective efficacy against all influenza A strains, high barrier to resistance and synergistic effects with approved antivirals, and our plans to report topline results of the Phase 1 study by the end of 2022. The words &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;should,&#8221; &#8220;plan,&#8221; &#8220;could,&#8221; &#8220;target,&#8221; &#8220;potential,&#8221; &#8220;is likely,&#8221; &#8220;will,&#8221; &#8220;expect&#8221; and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events. Some or all of the events anticipated by these forward-looking statements may not occur. Important factors that could cause actual results to differ from those in the forward-looking statements include, but are not limited to, the risks and uncertainties arising from any future impact of COVID-19 (including long-term or pervasive effects of the virus), inflation, interest rate increases and the war in Ukraine on the U.K. and global economy and on our Company, including supply chain disruptions and our continued ability to proceed with our programs, including our influenza A program, the ability of the contract research organization to recruit patients into clinical trials, the results of future preclinical and clinical studies, and general risks arising from clinical trials. Further information on our risk factors is contained in our filings with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2021. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.



Investor Contact:LHA Investor RelationsJody Cain310-691-7100jcain@lhai.com&nbsp;



Media Contact:JQA PartnersJules Abraham917-885-7378Jabraham@jqapartners.com



+# # #







Source: Cocrystal Pharma, Inc.



Released December 1, 2022

Release - Cocrystal Pharma Highlights Progress with CC-42344 as a Potential Oral Treatment for Pandemic and Seasonal Influenza A at the World Antiviral Congress 2022

Biotechnology

COCP

Cocrystal Pharma

<figure class="wp-block-image aligncenter size-full is-resized"><img src="https://dashboard.channelchek.com/wp-content/uploads/2020/10/mgmlf_logo.png" alt="" class="wp-image-49267" width="207" height="207"/></figure>



<a href="http://www.channelchek.com/company/mgmlf">Research, News, and Market Data on MGMLF</a>



Vancouver, British Columbia--(Newsfile Corp. - December 1, 2022) -&nbsp;Maple Gold Mines Ltd. (TSXV: MGM) (OTCQB: MGMLF) (FSE: M3G)&nbsp;("Maple Gold" or the "Company") is pleased to announce that, further to the Company's news release on October 7, 2022, two (2) additional drill rigs have been secured, bringing the number of rigs at site up to five (5) in total. The additional rigs will help to complete the previously announced 6,000 metre ("m") deep drilling program in the Telbel mine area ("Telbel") at the Joutel Project ("Joutel"), which is held by a 50/50 joint venture (the "JV") between the Company and Agnico Eagle Mines Limited, as well as initiate the previously announced 10,000 m deep drilling program at the JV's Douay Project ("Douay") in the coming weeks.



Three (3) drill rigs are currently turning at the Company's 100%-controlled Eagle Mine Property ("Eagle"), where the previously announced 5,000 m Phase III drill program is expected to be completed by year-end. A fourth drill rig was added in late October and continues to drill at Telbel. The fifth drill rig has arrived at site and been mobilized to Telbel, where the Company expects to complete the 6,000 m program by January 2023. As drill rigs become available from Eagle and Telbel, they will be relocated to Douay and the Company anticipates having all five (5) drill rigs turning at Douay during Q1/2023 to expedite the 10,000 m deep drilling program.



The Company has now released assay results corresponding to approximately 13,300 m of 2022 drilling across Eagle and Douay, with approximately 10,300 m of additional drilling completed to-date at Eagle and Telbel.



"With five drill rigs actively turning on our Québec projects, the Company remains on track to meet our targeted 2022 drill metreage,"&nbsp;stated Matthew Hornor, President and CEO of Maple Gold.&nbsp;"We look forward to additional results from drilling at Eagle and Telbel and to commencing the deep drill program at Douay to test potential depth extensions below the current pit-constrained mineral resource as soon as drill rigs from Eagle and Telbel become available."



Deep drilling at Telbel and Douay is being funded by a previously announced C$4.8-million supplemental Year Two JV exploration budget (see news from May 18, 2022). The JV's additional Year Three (February 2, annual start date) drilling and exploration plans will be designed by the partners in late Q4 2022 and finalized during early Q1 2023.



<figure class="wp-block-image aligncenter size-full"><img src="https://dashboard.channelchek.com/wp-content/uploads/2022/12/mgmlf.jpg" alt="" class="wp-image-53410"/></figure>



<a href="https://images.newsfilecorp.com/files/3077/146401_b9b802b32407eb44_001full.jpg"></a>  Pictured above: Multiple drill rigs in action at Eagle as exploration drilling ramps up along the Joutel Mine Complex, which produced 1.1 Moz at 6.5 g/t Au from 1974 - 1993.   To view an enhanced version of this graphic, please visit: <a href="https://images.newsfilecorp.com/files/3077/146401_b9b802b32407eb44_001full.jpg">https://images.newsfilecorp.com/files/3077/146401_b9b802b32407eb44_001full.jpg</a>



About Maple Gold



Maple Gold Mines Ltd. is a Canadian advanced exploration company in a 50/50 joint venture with Agnico Eagle Mines Limited to jointly advance the district-scale Douay and Joutel gold projects located in Québec's prolific Abitibi Greenstone Gold Belt. The projects benefit from exceptional infrastructure and access and boast ~400 km² of highly prospective ground including an established gold resource at Douay (SLR 2022) that holds significant expansion potential as well as the past-producing Eagle, Telbel and Eagle West mines at Joutel. In addition, the Company holds an exclusive option to acquire 100% of the Eagle Mine Property.



The district-scale property package also hosts a significant number of regional exploration targets along a 55 km strike length of the Casa Berardi Deformation Zone that have yet to be tested through drilling, making the project ripe for new gold and polymetallic discoveries. The Company is well capitalized and is currently focused on carrying out exploration and drill programs to grow resources and make new discoveries to establish an exciting new gold district in the heart of the Abitibi. For more information, please visit&nbsp;<a href="https://www.newsfilecorp.com/redirect/w2DLyc7552">www.maplegoldmines.com</a>.



ON BEHALF OF MAPLE GOLD MINES LTD.



"Matthew Hornor"



B. Matthew Hornor, President &amp; CEO



For Further Information Please Contact:



Mr. Joness Lang Executive Vice-President Cell: 778.686.6836 Email:&nbsp;<a href="mailto:jlang@maplegoldmines.com">jlang@maplegoldmines.com</a>



Mr. Jeff Uppal Manager, Investor Relations Cell: 778.977.4724 Email:&nbsp;<a href="mailto:juppal@maplegoldmines.com">juppal@maplegoldmines.com</a>



NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS PRESS RELEASE.



Forward-Looking Statements: This press release contains "forward-looking information" and "forward-looking statements" (collectively referred to as "forward-looking statements") within the meaning of applicable Canadian securities legislation in Canada, including statements about exploration work and results from current and future work programs. Forward-looking statements are based on assumptions, uncertainties and management's best estimate of future events. Actual events or results could differ materially from the Company's expectations and projections. Investors are cautioned that forward-looking statements involve risks and uncertainties. Accordingly, readers should not place undue reliance on forward-looking statements. For a more detailed discussion of such risks and other factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements, refer to Maple Gold Mines Ltd.'s filings with Canadian securities regulators available on&nbsp;<a href="https://www.newsfilecorp.com/redirect/gxMNqcwLLo">www.sedar.com</a>&nbsp;or the Company's website at&nbsp;<a href="https://www.newsfilecorp.com/redirect/p4M3qhrvvY">www.maplegoldmines.com</a>.&nbsp;The Company does not intend, and expressly disclaims any intention or obligation to, update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.



To view the source version of this press release, please visit&nbsp;<a href="https://www.newsfilecorp.com/redirect/YzMkmc3DDG">https://www.newsfilecorp.com/release/146401</a>

<div class="wp-block-image">
<figure class="aligncenter size-full is-resized"><img decoding="async" loading="lazy" src="https://dashboard.channelchek.com/wp-content/uploads/2020/10/mgmlf_logo.png" alt="" class="wp-image-49267" width="207" height="207" srcset="https://dashboard.channelchek.com/wp-content/uploads/2020/10/mgmlf_logo.png 386w, https://dashboard.channelchek.com/wp-content/uploads/2020/10/mgmlf_logo-300x300.png 300w, https://dashboard.channelchek.com/wp-content/uploads/2020/10/mgmlf_logo-150x150.png 150w" sizes="(max-width: 207px) 100vw, 207px" /></figure></div>


<a href="http://www.channelchek.com/company/mgmlf">Research, News, and Market Data on MGMLF</a>



Vancouver, British Columbia&#8211;(Newsfile Corp. &#8211; December 1, 2022) &#8211;&nbsp;Maple Gold Mines Ltd. (TSXV: MGM) (OTCQB: MGMLF) (FSE: M3G)&nbsp;(&#8220;Maple Gold&#8221; or the &#8220;Company&#8220;) is pleased to announce that, further to the Company&#8217;s news release on October 7, 2022, two (2) additional drill rigs have been secured, bringing the number of rigs at site up to five (5) in total. The additional rigs will help to complete the previously announced 6,000 metre (&#8220;m&#8221;) deep drilling program in the Telbel mine area (&#8220;Telbel&#8221;) at the Joutel Project (&#8220;Joutel&#8221;), which is held by a 50/50 joint venture (the &#8220;JV&#8221;) between the Company and Agnico Eagle Mines Limited, as well as initiate the previously announced 10,000 m deep drilling program at the JV&#8217;s Douay Project (&#8220;Douay&#8221;) in the coming weeks.



Three (3) drill rigs are currently turning at the Company&#8217;s 100%-controlled Eagle Mine Property (&#8220;Eagle&#8221;), where the previously announced 5,000 m Phase III drill program is expected to be completed by year-end. A fourth drill rig was added in late October and continues to drill at Telbel. The fifth drill rig has arrived at site and been mobilized to Telbel, where the Company expects to complete the 6,000 m program by January 2023. As drill rigs become available from Eagle and Telbel, they will be relocated to Douay and the Company anticipates having all five (5) drill rigs turning at Douay during Q1/2023 to expedite the 10,000 m deep drilling program.



The Company has now released assay results corresponding to approximately 13,300 m of 2022 drilling across Eagle and Douay, with approximately 10,300 m of additional drilling completed to-date at Eagle and Telbel.



&#8220;With five drill rigs actively turning on our Québec projects, the Company remains on track to meet our targeted 2022 drill metreage,&#8221;&nbsp;stated Matthew Hornor, President and CEO of Maple Gold.&nbsp;&#8220;We look forward to additional results from drilling at Eagle and Telbel and to commencing the deep drill program at Douay to test potential depth extensions below the current pit-constrained mineral resource as soon as drill rigs from Eagle and Telbel become available.&#8221;



Deep drilling at Telbel and Douay is being funded by a previously announced C$4.8-million supplemental Year Two JV exploration budget (see news from May 18, 2022). The JV&#8217;s additional Year Three (February 2, annual start date) drilling and exploration plans will be designed by the partners in late Q4 2022 and finalized during early Q1 2023.


<div class="wp-block-image">
<figure class="aligncenter size-full"><img decoding="async" loading="lazy" width="413" height="309" src="https://dashboard.channelchek.com/wp-content/uploads/2022/12/mgmlf.jpg" alt="" class="wp-image-53410" srcset="https://dashboard.channelchek.com/wp-content/uploads/2022/12/mgmlf.jpg 413w, https://dashboard.channelchek.com/wp-content/uploads/2022/12/mgmlf-300x224.jpg 300w" sizes="(max-width: 413px) 100vw, 413px" /></figure></div>


<a href="https://images.newsfilecorp.com/files/3077/146401_b9b802b32407eb44_001full.jpg"></a>  Pictured above: Multiple drill rigs in action at Eagle as exploration drilling ramps up along the Joutel Mine Complex, which produced 1.1 Moz at 6.5 g/t Au from 1974 &#8211; 1993.   To view an enhanced version of this graphic, please visit: <a href="https://images.newsfilecorp.com/files/3077/146401_b9b802b32407eb44_001full.jpg">https://images.newsfilecorp.com/files/3077/146401_b9b802b32407eb44_001full.jpg</a>



About Maple Gold



Maple Gold Mines Ltd. is a Canadian advanced exploration company in a 50/50 joint venture with Agnico Eagle Mines Limited to jointly advance the district-scale Douay and Joutel gold projects located in Québec&#8217;s prolific Abitibi Greenstone Gold Belt. The projects benefit from exceptional infrastructure and access and boast ~400 km² of highly prospective ground including an established gold resource at Douay (SLR 2022) that holds significant expansion potential as well as the past-producing Eagle, Telbel and Eagle West mines at Joutel. In addition, the Company holds an exclusive option to acquire 100% of the Eagle Mine Property.



The district-scale property package also hosts a significant number of regional exploration targets along a 55 km strike length of the Casa Berardi Deformation Zone that have yet to be tested through drilling, making the project ripe for new gold and polymetallic discoveries. The Company is well capitalized and is currently focused on carrying out exploration and drill programs to grow resources and make new discoveries to establish an exciting new gold district in the heart of the Abitibi. For more information, please visit&nbsp;<a href="https://www.newsfilecorp.com/redirect/w2DLyc7552">www.maplegoldmines.com</a>.



ON BEHALF OF MAPLE GOLD MINES LTD.



&#8220;Matthew Hornor&#8221;



B. Matthew Hornor, President &amp; CEO



For Further Information Please Contact:



Mr. Joness Lang Executive Vice-President Cell: 778.686.6836 Email:&nbsp;<a href="mailto:jlang@maplegoldmines.com">jlang@maplegoldmines.com</a>



Mr. Jeff Uppal Manager, Investor Relations Cell: 778.977.4724 Email:&nbsp;<a href="mailto:juppal@maplegoldmines.com">juppal@maplegoldmines.com</a>



NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS PRESS RELEASE.



Forward-Looking Statements: This press release contains &#8220;forward-looking information&#8221; and &#8220;forward-looking statements&#8221; (collectively referred to as &#8220;forward-looking statements&#8221;) within the meaning of applicable Canadian securities legislation in Canada, including statements about exploration work and results from current and future work programs. Forward-looking statements are based on assumptions, uncertainties and management&#8217;s best estimate of future events. Actual events or results could differ materially from the Company&#8217;s expectations and projections. Investors are cautioned that forward-looking statements involve risks and uncertainties. Accordingly, readers should not place undue reliance on forward-looking statements. For a more detailed discussion of such risks and other factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements, refer to Maple Gold Mines Ltd.&#8217;s filings with Canadian securities regulators available on&nbsp;<a href="https://www.newsfilecorp.com/redirect/gxMNqcwLLo">www.sedar.com</a>&nbsp;or the Company&#8217;s website at&nbsp;<a href="https://www.newsfilecorp.com/redirect/p4M3qhrvvY">www.maplegoldmines.com</a>.&nbsp;The Company does not intend, and expressly disclaims any intention or obligation to, update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.



To view the source version of this press release, please visit&nbsp;<a href="https://www.newsfilecorp.com/redirect/YzMkmc3DDG">https://www.newsfilecorp.com/release/146401</a>

Research, News, and Market Data on MGMLF



Vancouver, British Columbia&#8211;(Newsfile Corp. &#8211; December 1, 2022) &#8211;&nbsp;Maple Gold Mines Ltd. (TSXV: MGM) (OTCQB: MGMLF) (FSE: M3G)&nbsp;(&#8220;Maple Gold&#8221; or the &#8220;Company&#8220;) is pleased to announce that, further to the Company&#8217;s news release on October 7, 2022, two (2) additional drill rigs have been secured, bringing the number of rigs at site up to five (5) in total. The additional rigs will help to complete the previously announced 6,000 metre (&#8220;m&#8221;) deep drilling program in the Telbel mine area (&#8220;Telbel&#8221;) at the Joutel Project (&#8220;Joutel&#8221;), which is held by a 50/50 joint venture (the &#8220;JV&#8221;) between the Company and Agnico Eagle Mines Limited, as well as initiate the previously announced 10,000 m deep drilling program at the JV&#8217;s Douay Project (&#8220;Douay&#8221;) in the coming weeks.



Three (3) drill rigs are currently turning at the Company&#8217;s 100%-controlled Eagle Mine Property (&#8220;Eagle&#8221;), where the previously announced 5,000 m Phase III drill program is expected to be completed by year-end. A fourth drill rig was added in late October and continues to drill at Telbel. The fifth drill rig has arrived at site and been mobilized to Telbel, where the Company expects to complete the 6,000 m program by January 2023. As drill rigs become available from Eagle and Telbel, they will be relocated to Douay and the Company anticipates having all five (5) drill rigs turning at Douay during Q1/2023 to expedite the 10,000 m deep drilling program.



The Company has now released assay results corresponding to approximately 13,300 m of 2022 drilling across Eagle and Douay, with approximately 10,300 m of additional drilling completed to-date at Eagle and Telbel.



&#8220;With five drill rigs actively turning on our Québec projects, the Company remains on track to meet our targeted 2022 drill metreage,&#8221;&nbsp;stated Matthew Hornor, President and CEO of Maple Gold.&nbsp;&#8220;We look forward to additional results from drilling at Eagle and Telbel and to commencing the deep drill program at Douay to test potential depth extensions below the current pit-constrained mineral resource as soon as drill rigs from Eagle and Telbel become available.&#8221;



Deep drilling at Telbel and Douay is being funded by a previously announced C$4.8-million supplemental Year Two JV exploration budget (see news from May 18, 2022). The JV&#8217;s additional Year Three (February 2, annual start date) drilling and exploration plans will be designed by the partners in late Q4 2022 and finalized during early Q1 2023.






 Pictured above: Multiple drill rigs in action at Eagle as exploration drilling ramps up along the Joutel Mine Complex, which produced 1.1 Moz at 6.5 g/t Au from 1974 &#8211; 1993. To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/3077/146401_b9b802b32407eb44_001full.jpg



About Maple Gold



Maple Gold Mines Ltd. is a Canadian advanced exploration company in a 50/50 joint venture with Agnico Eagle Mines Limited to jointly advance the district-scale Douay and Joutel gold projects located in Québec&#8217;s prolific Abitibi Greenstone Gold Belt. The projects benefit from exceptional infrastructure and access and boast ~400 km² of highly prospective ground including an established gold resource at Douay (SLR 2022) that holds significant expansion potential as well as the past-producing Eagle, Telbel and Eagle West mines at Joutel. In addition, the Company holds an exclusive option to acquire 100% of the Eagle Mine Property.



The district-scale property package also hosts a significant number of regional exploration targets along a 55 km strike length of the Casa Berardi Deformation Zone that have yet to be tested through drilling, making the project ripe for new gold and polymetallic discoveries. The Company is well capitalized and is currently focused on carrying out exploration and drill programs to grow resources and make new discoveries to establish an exciting new gold district in the heart of the Abitibi. For more information, please visit&nbsp;www.maplegoldmines.com.



ON BEHALF OF MAPLE GOLD MINES LTD.



&#8220;Matthew Hornor&#8221;



B. Matthew Hornor, President &amp; CEO



For Further Information Please Contact:



Mr. Joness LangExecutive Vice-PresidentCell: 778.686.6836Email:&nbsp;jlang@maplegoldmines.com



Mr. Jeff UppalManager, Investor RelationsCell: 778.977.4724Email:&nbsp;juppal@maplegoldmines.com



NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS PRESS RELEASE.



Forward-Looking Statements:This press release contains &#8220;forward-looking information&#8221; and &#8220;forward-looking statements&#8221; (collectively referred to as &#8220;forward-looking statements&#8221;) within the meaning of applicable Canadian securities legislation in Canada, including statements about exploration work and results from current and future work programs. Forward-looking statements are based on assumptions, uncertainties and management&#8217;s best estimate of future events. Actual events or results could differ materially from the Company&#8217;s expectations and projections. Investors are cautioned that forward-looking statements involve risks and uncertainties. Accordingly, readers should not place undue reliance on forward-looking statements. For a more detailed discussion of such risks and other factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements, refer to Maple Gold Mines Ltd.&#8217;s filings with Canadian securities regulators available on&nbsp;www.sedar.com&nbsp;or the Company&#8217;s website at&nbsp;www.maplegoldmines.com.&nbsp;The Company does not intend, and expressly disclaims any intention or obligation to, update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.



To view the source version of this press release, please visit&nbsp;https://www.newsfilecorp.com/release/146401

Release - Maple Gold Ramps Up Winter Exploration Activities with Five Drill Rigs Now Mobilized at Eagle and Joutel

Maple Gold Mines

MGMLF

Natural Resources

<figure class="wp-block-image aligncenter size-full is-resized"><img src="https://dashboard.channelchek.com/wp-content/uploads/2022/09/hhs-logo-pr.png" alt="" class="wp-image-49640" width="196" height="196"/></figure>



<a href="http://www.channelchek.com/company/hhs">Research, News, and Market Data on HHS</a>



Thursday, December 1, 2022 9:00 AM



CHELMSFORD, MA / ACCESSWIRE / December 1, 2022 /&nbsp;<a href="https://pr.report/NiIRolqB">Harte Hanks Inc.</a>&nbsp;(NASDAQ:HHS), a leading global customer experience company, announced today that it has completed the acquisition of InsideOut Solutions, LLC, an inside sales optimization firm. InsideOut offers inbound and outbound sales outsourcing and experimentation services for partners globally.



"With the acquisition of InsideOut and its inside sales capabilities, Harte Hanks is uniquely positioned to help customers drive growth by optimizing sales and marketing demand generation programs," commented Brian Linscott, Harte Hanks CEO. "We couldn't be more pleased with this acquisition, and we are excited to welcome the talented InsideOut team to Harte Hanks. The acquisition of InsideOut will not only provide short-term revenue growth opportunities, but also will be immediately accretive to HHS value. We anticipate cost synergies alone will drive the post-acquisition valuation in the 3-4x EBITDA range."



"Harte Hanks' proven ability to drive marketing leads with our cross-segment Marketing Services and Customer Care team and InsideOut's talent, processes, and experience in delivering sales-qualified leads will drive higher value for our clients," added Linscott. "InsideOut clients can now come to Harte Hanks for a broad scope of marketing (including data &amp; analytics), customer care, fulfillment and logistics services."



"We are thrilled to have InsideOut join the Harte Hanks team. What attracted us to Harte Hanks was the clear alignment in culture and values, the like-minded commitment to our partners and a focus on our people, who we believe are the cornerstone for our successes," remarked Christina Cherry, CEO of InsideOut. Ms. Cherry continued, "This transaction enables us to scale faster and support further growth for our partners, and to provide additional opportunities for our exceptional team of employees, given Harte Hanks' broader scope of services."



The combined organizations will begin operations as Harte Hanks on December 1, 2022, with 136 employees joining the Harte Hanks team. Harte Hanks also adds a seventh location to its North American offices with the acquisition of InsideOut's 7,500-square-foot headquarter facility based in St. Petersburg, Florida.



Transaction Details Harte Hanks has acquired substantially all the assets of InsideOut on December 1, 2022 for a purchase price of $7.5 million, to be paid with a combination of cash and shares of HHS common stock.



Additional information about the completed acquisition will be provided in a Current Report on Form 8-K filed by Harte Hanks with the Securities and Exchange Commission and available at&nbsp;<a href="https://pr.report/kXwTJ0Fl">www.sec.gov</a>.



About InsideOut: InsideOut specializes in building, scaling and optimizing inside sales initiatives for some of the world's largest corporations. In the last seven years the Florida-based organization has partnered with leading Fortune 500 companies including Google, IBM, T-Mobile and Honeywell.



Deploying an analytically driven approach to inside sales experimentation and testing, InsideOut has gained global recognition as one of the most innovative revenue development organizations in the United States. For more information, visit&nbsp;<a href="https://pr.report/Sa-m2WTr">insideoutlab.com</a>.



InsideOut was represented in the transaction by its investment banker&nbsp;<a href="https://pr.report/2hCOAZrM">Novistra Capital</a>.



About Harte Hanks: <a href="https://pr.report/FDzls5Qu">Harte Hanks</a>&nbsp;(NASDAQ:HHS) is a leading global customer experience company that partners with clients to provide them with CX strategy, data-driven analytics and actionable insights combined with seamless program execution to better understand, attract and engage their customers.



Using its resources and talent in the areas of Customer Care, Fulfillment, Logistics, and Marketing Services, Harte Hanks has driven results for some of the world's premier brands, including Bank of America, GlaxoSmithKline, Unilever, Pfizer, HBOMax, Volvo, Ford, FedEx, Midea, Sony and IBM. Headquartered in Chelmsford, Massachusetts, Harte Hanks has over 2,500 employees in offices across the Americas, Europe, and Asia Pacific. For more information, visit&nbsp;<a href="https://pr.report/gyO3RqzE">hartehanks.com</a>.



For media inquiries, contact Jennifer London at&nbsp;<a href="mailto:Jen.London@HarteHanks.com">Jen.London@HarteHanks.com</a>.



SOURCE:&nbsp;Harte Hanks, Inc.

<div class="wp-block-image">
<figure class="aligncenter size-full is-resized"><img decoding="async" loading="lazy" src="https://dashboard.channelchek.com/wp-content/uploads/2022/09/hhs-logo-pr.png" alt="" class="wp-image-49640" width="196" height="196" srcset="https://dashboard.channelchek.com/wp-content/uploads/2022/09/hhs-logo-pr.png 242w, https://dashboard.channelchek.com/wp-content/uploads/2022/09/hhs-logo-pr-150x150.png 150w" sizes="(max-width: 196px) 100vw, 196px" /></figure></div>


<a href="http://www.channelchek.com/company/hhs">Research, News, and Market Data on HHS</a>



Thursday, December 1, 2022 9:00 AM



CHELMSFORD, MA / ACCESSWIRE / December 1, 2022 /&nbsp;<a href="https://pr.report/NiIRolqB">Harte Hanks Inc.</a>&nbsp;(NASDAQ:HHS), a leading global customer experience company, announced today that it has completed the acquisition of InsideOut Solutions, LLC, an inside sales optimization firm. InsideOut offers inbound and outbound sales outsourcing and experimentation services for partners globally.



&#8220;With the acquisition of InsideOut and its inside sales capabilities, Harte Hanks is uniquely positioned to help customers drive growth by optimizing sales and marketing demand generation programs,&#8221; commented Brian Linscott, Harte Hanks CEO. &#8220;We couldn&#8217;t be more pleased with this acquisition, and we are excited to welcome the talented InsideOut team to Harte Hanks. The acquisition of InsideOut will not only provide short-term revenue growth opportunities, but also will be immediately accretive to HHS value. We anticipate cost synergies alone will drive the post-acquisition valuation in the 3-4x EBITDA range.&#8221;



&#8220;Harte Hanks&#8217; proven ability to drive marketing leads with our cross-segment Marketing Services and Customer Care team and InsideOut&#8217;s talent, processes, and experience in delivering sales-qualified leads will drive higher value for our clients,&#8221; added Linscott. &#8220;InsideOut clients can now come to Harte Hanks for a broad scope of marketing (including data &amp; analytics), customer care, fulfillment and logistics services.&#8221;



&#8220;We are thrilled to have InsideOut join the Harte Hanks team. What attracted us to Harte Hanks was the clear alignment in culture and values, the like-minded commitment to our partners and a focus on our people, who we believe are the cornerstone for our successes,&#8221; remarked Christina Cherry, CEO of InsideOut. Ms. Cherry continued, &#8220;This transaction enables us to scale faster and support further growth for our partners, and to provide additional opportunities for our exceptional team of employees, given Harte Hanks&#8217; broader scope of services.&#8221;



The combined organizations will begin operations as Harte Hanks on December 1, 2022, with 136 employees joining the Harte Hanks team. Harte Hanks also adds a seventh location to its North American offices with the acquisition of InsideOut&#8217;s 7,500-square-foot headquarter facility based in St. Petersburg, Florida.



Transaction Details Harte Hanks has acquired substantially all the assets of InsideOut on December 1, 2022 for a purchase price of $7.5 million, to be paid with a combination of cash and shares of HHS common stock.



Additional information about the completed acquisition will be provided in a Current Report on Form 8-K filed by Harte Hanks with the Securities and Exchange Commission and available at&nbsp;<a href="https://pr.report/kXwTJ0Fl">www.sec.gov</a>.



About InsideOut: InsideOut specializes in building, scaling and optimizing inside sales initiatives for some of the world&#8217;s largest corporations. In the last seven years the Florida-based organization has partnered with leading Fortune 500 companies including Google, IBM, T-Mobile and Honeywell.



Deploying an analytically driven approach to inside sales experimentation and testing, InsideOut has gained global recognition as one of the most innovative revenue development organizations in the United States. For more information, visit&nbsp;<a href="https://pr.report/Sa-m2WTr">insideoutlab.com</a>.



InsideOut was represented in the transaction by its investment banker&nbsp;<a href="https://pr.report/2hCOAZrM">Novistra Capital</a>.



About Harte Hanks: <a href="https://pr.report/FDzls5Qu">Harte Hanks</a>&nbsp;(NASDAQ:HHS) is a leading global customer experience company that partners with clients to provide them with CX strategy, data-driven analytics and actionable insights combined with seamless program execution to better understand, attract and engage their customers.



Using its resources and talent in the areas of Customer Care, Fulfillment, Logistics, and Marketing Services, Harte Hanks has driven results for some of the world&#8217;s premier brands, including Bank of America, GlaxoSmithKline, Unilever, Pfizer, HBOMax, Volvo, Ford, FedEx, Midea, Sony and IBM. Headquartered in Chelmsford, Massachusetts, Harte Hanks has over 2,500 employees in offices across the Americas, Europe, and Asia Pacific. For more information, visit&nbsp;<a href="https://pr.report/gyO3RqzE">hartehanks.com</a>.



For media inquiries, contact Jennifer London at&nbsp;<a href="mailto:Jen.London@HarteHanks.com">Jen.London@HarteHanks.com</a>.



SOURCE:&nbsp;Harte Hanks, Inc.

Research, News, and Market Data on HHS



Thursday, December 1, 2022 9:00 AM



CHELMSFORD, MA / ACCESSWIRE / December 1, 2022 /&nbsp;Harte Hanks Inc.&nbsp;(NASDAQ:HHS), a leading global customer experience company, announced today that it has completed the acquisition of InsideOut Solutions, LLC, an inside sales optimization firm. InsideOut offers inbound and outbound sales outsourcing and experimentation services for partners globally.



&#8220;With the acquisition of InsideOut and its inside sales capabilities, Harte Hanks is uniquely positioned to help customers drive growth by optimizing sales and marketing demand generation programs,&#8221; commented Brian Linscott, Harte Hanks CEO. &#8220;We couldn&#8217;t be more pleased with this acquisition, and we are excited to welcome the talented InsideOut team to Harte Hanks. The acquisition of InsideOut will not only provide short-term revenue growth opportunities, but also will be immediately accretive to HHS value. We anticipate cost synergies alone will drive the post-acquisition valuation in the 3-4x EBITDA range.&#8221;



&#8220;Harte Hanks&#8217; proven ability to drive marketing leads with our cross-segment Marketing Services and Customer Care team and InsideOut&#8217;s talent, processes, and experience in delivering sales-qualified leads will drive higher value for our clients,&#8221; added Linscott. &#8220;InsideOut clients can now come to Harte Hanks for a broad scope of marketing (including data &amp; analytics), customer care, fulfillment and logistics services.&#8221;



&#8220;We are thrilled to have InsideOut join the Harte Hanks team. What attracted us to Harte Hanks was the clear alignment in culture and values, the like-minded commitment to our partners and a focus on our people, who we believe are the cornerstone for our successes,&#8221; remarked Christina Cherry, CEO of InsideOut. Ms. Cherry continued, &#8220;This transaction enables us to scale faster and support further growth for our partners, and to provide additional opportunities for our exceptional team of employees, given Harte Hanks&#8217; broader scope of services.&#8221;



The combined organizations will begin operations as Harte Hanks on December 1, 2022, with 136 employees joining the Harte Hanks team. Harte Hanks also adds a seventh location to its North American offices with the acquisition of InsideOut&#8217;s 7,500-square-foot headquarter facility based in St. Petersburg, Florida.



Transaction DetailsHarte Hanks has acquired substantially all the assets of InsideOut on December 1, 2022 for a purchase price of $7.5 million, to be paid with a combination of cash and shares of HHS common stock.



Additional information about the completed acquisition will be provided in a Current Report on Form 8-K filed by Harte Hanks with the Securities and Exchange Commission and available at&nbsp;www.sec.gov.



About InsideOut:InsideOut specializes in building, scaling and optimizing inside sales initiatives for some of the world&#8217;s largest corporations. In the last seven years the Florida-based organization has partnered with leading Fortune 500 companies including Google, IBM, T-Mobile and Honeywell.



Deploying an analytically driven approach to inside sales experimentation and testing, InsideOut has gained global recognition as one of the most innovative revenue development organizations in the United States. For more information, visit&nbsp;insideoutlab.com.



InsideOut was represented in the transaction by its investment banker&nbsp;Novistra Capital.



About Harte Hanks:Harte Hanks&nbsp;(NASDAQ:HHS) is a leading global customer experience company that partners with clients to provide them with CX strategy, data-driven analytics and actionable insights combined with seamless program execution to better understand, attract and engage their customers.



Using its resources and talent in the areas of Customer Care, Fulfillment, Logistics, and Marketing Services, Harte Hanks has driven results for some of the world&#8217;s premier brands, including Bank of America, GlaxoSmithKline, Unilever, Pfizer, HBOMax, Volvo, Ford, FedEx, Midea, Sony and IBM. Headquartered in Chelmsford, Massachusetts, Harte Hanks has over 2,500 employees in offices across the Americas, Europe, and Asia Pacific. For more information, visit&nbsp;hartehanks.com.



For media inquiries, contact Jennifer London at&nbsp;Jen.London@HarteHanks.com.



SOURCE:&nbsp;Harte Hanks, Inc.

Release - Harte Hanks Acquires InsideOut Solutions, LLC, for $7.5 million

Harte Hanks

Marketing

<figure class="wp-block-image aligncenter size-full is-resized"><img src="https://dashboard.channelchek.com/wp-content/uploads/2022/09/salm-logo-pr.png" alt="" class="wp-image-49115" width="275" height="98"/></figure>



Research, News, and Market Data on SALM 



December 01, 2022 9:00am EST



IRVING, Texas--(BUSINESS WIRE)--&nbsp;<a href="http://www.salemmediagroup.com/">Salem Media Group, Inc.</a>&nbsp;(NASDAQ: SALM), announced today that it will present at the 17th&nbsp;annual Singular Research Best of the Uncovered Investor Conference in San Francisco on December 8, 2022 at 3:45 PM Central Time. The presentation will be available on the investor relations portion of the company’s website&nbsp;<a href="http://www.salemmedia.com/">www.salemmedia.com</a>&nbsp;prior to the company’s presentation.



ABOUT SINGULAR RESEARCH:



Singular Research aims to be the most trusted supplier of independent, trusted, single-sources research on small-to-micro cap companies to the small-to-medium sized Hedge Fund manager. Singular Research provides quarterly updates for 40 to 70 companies and makes recommendations.



Singular strives to achieve goals by finding under or overvalued securities. Singular’s goal is to provide initiation reports and quarterly updates for approximately 40 micro to small cap companies. In most cases, Singular analysts research companies that are not covered by any other firms.



Singular provides honest advice. Independent analysts have no financial interest in the stocks covered. Analysts are compensated based on the accuracy of their research calls not through trading commissions or potential deal flow.



ABOUT SALEM MEDIA GROUP:



Salem Media Group is America’s leading multimedia company specializing in Christian and conservative content, with media properties comprising radio, digital media and book and newsletter publishing. Each day Salem serves a loyal and dedicated audience of listeners and readers numbering in the millions nationally. With its unique programming focus, Salem provides compelling content, fresh commentary and relevant information from some of the most respected figures across the Christian and conservative media landscape. Learn more about Salem Media Group, Inc. at&nbsp;<a href="http://www.salemmedia.com/">www.salemmedia.com</a>,&nbsp;<a href="http://www.facebook.com/Salemmediagroup/">Facebook</a>&nbsp;and&nbsp;<a href="https://twitter.com/salemmediagrp/">Twitter</a>.



View source version on businesswire.com:&nbsp;<a href="https://www.businesswire.com/news/home/20221129006018/en/">https://www.businesswire.com/news/home/20221129006018/en/</a>



Evan D. Masyr Executive Vice President and Chief Financial Officer (805) 384-4512 <a href="mailto:evan@salemmedia.com">evan@salemmedia.com</a>



Source: Salem Media Group, Inc.



Released December 1, 2022

<div class="wp-block-image">
<figure class="aligncenter size-full is-resized"><img decoding="async" loading="lazy" src="https://dashboard.channelchek.com/wp-content/uploads/2022/09/salm-logo-pr.png" alt="" class="wp-image-49115" width="275" height="98" srcset="https://dashboard.channelchek.com/wp-content/uploads/2022/09/salm-logo-pr.png 350w, https://dashboard.channelchek.com/wp-content/uploads/2022/09/salm-logo-pr-300x107.png 300w" sizes="(max-width: 275px) 100vw, 275px" /></figure></div>


Research, News, and Market Data on SALM 



December 01, 2022 9:00am EST



IRVING, Texas&#8211;(BUSINESS WIRE)&#8211;&nbsp;<a href="http://www.salemmediagroup.com/">Salem Media Group, Inc.</a>&nbsp;(NASDAQ: SALM), announced today that it will present at the 17th&nbsp;annual Singular Research Best of the Uncovered Investor Conference in San Francisco on December 8, 2022 at 3:45 PM Central Time. The presentation will be available on the investor relations portion of the company’s website&nbsp;<a href="http://www.salemmedia.com/">www.salemmedia.com</a>&nbsp;prior to the company’s presentation.



ABOUT SINGULAR RESEARCH:



Singular Research aims to be the most trusted supplier of independent, trusted, single-sources research on small-to-micro cap companies to the small-to-medium sized Hedge Fund manager. Singular Research provides quarterly updates for 40 to 70 companies and makes recommendations.



Singular strives to achieve goals by finding under or overvalued securities. Singular’s goal is to provide initiation reports and quarterly updates for approximately 40 micro to small cap companies. In most cases, Singular analysts research companies that are not covered by any other firms.



Singular provides honest advice. Independent analysts have no financial interest in the stocks covered. Analysts are compensated based on the accuracy of their research calls not through trading commissions or potential deal flow.



ABOUT SALEM MEDIA GROUP:



Salem Media Group is America’s leading multimedia company specializing in Christian and conservative content, with media properties comprising radio, digital media and book and newsletter publishing. Each day Salem serves a loyal and dedicated audience of listeners and readers numbering in the millions nationally. With its unique programming focus, Salem provides compelling content, fresh commentary and relevant information from some of the most respected figures across the Christian and conservative media landscape. Learn more about Salem Media Group, Inc. at&nbsp;<a href="http://www.salemmedia.com/">www.salemmedia.com</a>,&nbsp;<a href="http://www.facebook.com/Salemmediagroup/">Facebook</a>&nbsp;and&nbsp;<a href="https://twitter.com/salemmediagrp/">Twitter</a>.



View source version on businesswire.com:&nbsp;<a href="https://www.businesswire.com/news/home/20221129006018/en/">https://www.businesswire.com/news/home/20221129006018/en/</a>



Evan D. Masyr Executive Vice President and Chief Financial Officer (805) 384-4512 <a href="mailto:evan@salemmedia.com">evan@salemmedia.com</a>



Source: Salem Media Group, Inc.



Released December 1, 2022

Research, News, and Market Data on SALM 



December 01, 2022 9:00am EST



IRVING, Texas&#8211;(BUSINESS WIRE)&#8211;&nbsp;Salem Media Group, Inc.&nbsp;(NASDAQ: SALM), announced today that it will present at the 17th&nbsp;annual Singular Research Best of the Uncovered Investor Conference in San Francisco on December 8, 2022 at 3:45 PM Central Time. The presentation will be available on the investor relations portion of the company’s website&nbsp;www.salemmedia.com&nbsp;prior to the company’s presentation.



ABOUT SINGULAR RESEARCH:



Singular Research aims to be the most trusted supplier of independent, trusted, single-sources research on small-to-micro cap companies to the small-to-medium sized Hedge Fund manager. Singular Research provides quarterly updates for 40 to 70 companies and makes recommendations.



Singular strives to achieve goals by finding under or overvalued securities. Singular’s goal is to provide initiation reports and quarterly updates for approximately 40 micro to small cap companies. In most cases, Singular analysts research companies that are not covered by any other firms.



Singular provides honest advice. Independent analysts have no financial interest in the stocks covered. Analysts are compensated based on the accuracy of their research calls not through trading commissions or potential deal flow.



ABOUT SALEM MEDIA GROUP:



Salem Media Group is America’s leading multimedia company specializing in Christian and conservative content, with media properties comprising radio, digital media and book and newsletter publishing. Each day Salem serves a loyal and dedicated audience of listeners and readers numbering in the millions nationally. With its unique programming focus, Salem provides compelling content, fresh commentary and relevant information from some of the most respected figures across the Christian and conservative media landscape. Learn more about Salem Media Group, Inc. at&nbsp;www.salemmedia.com,&nbsp;Facebook&nbsp;and&nbsp;Twitter.



View source version on businesswire.com:&nbsp;https://www.businesswire.com/news/home/20221129006018/en/



Evan D. MasyrExecutive Vice President and ChiefFinancial Officer(805) 384-4512evan@salemmedia.com



Source: Salem Media Group, Inc.



Released December 1, 2022

Release - Salem Media Group to Present at the Upcoming 17th Annual Singular Research Best of the Uncovered Investor Conference

Conservative

Multimedia

Salem Media Group

SALM

<figure class="wp-block-image aligncenter size-full is-resized"><img src="https://dashboard.channelchek.com/wp-content/uploads/2020/10/tnxp_logo.png" alt="" class="wp-image-49291" width="193" height="193"/></figure>



<a href="http://www.channelchek.com/company/tnxp">Research, News, and Market Data on TNXP</a>



December 01, 2022 7:00am EST



TNX-801 is Based on the Sequence of a Natural Isolate of Horsepox and is Believed Closer in Structure to Edward Jenner’s 1798 Vaccine than Modern Vaccinia Virus Vaccines Against Smallpox



Live-Virus Vaccine Platform Leverages Tonix’s Expanding Internal Development and Manufacturing Capabilities for Biologics



CHATHAM, N.J., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced that Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, presented data from the Company’s TNX-801 (live horsepox virus vaccine) smallpox and monkeypox vaccine development program in an oral presentation at the World Vaccine and Immunotherapy Congress 2022, being held in San Diego, Calif., November 28 - December 1, 2022. A copy of the Company’s presentation is available under the&nbsp;<a href="https://www.globenewswire.com/Tracker?data=cMe7ZFL33JzxYoCOdJR95wdprBIDRMShXD7AINhGpmj9atMEZQr2Mu5q-Z9EISUg-gsQcnqAlwyJi2pnpe9SytpSyVIlhwtZa-ltUVuqKmigK9nHrv9M0dAU0yiMLJ7EybOgsD-hsZjXqy5chQoGrQ==" target="_blank" rel="noreferrer noopener">Scientific Presentations</a>&nbsp;tab of the Tonix website at&nbsp;<a href="https://www.globenewswire.com/Tracker?data=8b-Jp7UIzO4GKYR5s_UbaxaxlyWnOu-ZPVF_vp8b40ZoYNVg0UsYCPEH5sH3L9rZVD2u1kkNxV61thEHxFR_fCZWcB2JERyT61s4AflAM3k=" target="_blank" rel="noreferrer noopener">www.tonixpharma.com</a>



“TNX-801 is a live virus vaccine that we believe is closer to the smallpox vaccines used in the U.S. and Europe before 1900 than the modern vaccinia smallpox vaccines. TNX-801 has reduced virulence in animals, and we believe it has the potential for widespread use to protect against monkeypox,” said Seth Lederman, M.D., President and Chief Executive Officer. “Recent global outbreaks of monkeypox have highlighted the need to be prepared with a vaccine that provides durable immunity and blocks forward transmission. Tonix’s live virus vaccine technology is designed to achieve these outcomes.”



The oral presentation titled, “Live Virus Smallpox and Monkeypox Vaccine,” describes the history of live virus vaccines and rationale for the development of the Company’s Recombinant Pox Virus (RPV) platform, including TNX-801 to protect against monkeypox and smallpox. The presentation describes the origins of immunization, beginning with the first live virus vaccine invented by Dr. Edward Jenner in 1798. The inoculation procedure was called “vaccination” and the inoculum material was initially obtained from lesions on cows affected by a mild disease known as cowpox. However, Dr. Jenner suspected that cowpox originated from horses8,which led to immunization using material directly obtained from horses. This procedure was sometimes called “equination”. Equination and vaccination were practiced side-by-side in Europe13,14. Today, molecular analysis of DNA sequences from archaic smallpox vaccines suggests that TNX-801 is closer than modern smallpox vaccinia vaccines to the vaccine discovered and disseminated by Dr. Edward Jenner6-8.



As presented at the Canadian Society for Virology in June 2022, non-human primates vaccinated with TNX-801 were fully protected with sterilizing immunity from a challenge with intra-tracheal monkeypox.



In July 2022, the Company announced a collaboration with the Kenya Medical Research Institute (KEMRI) to seek regulatory approval for conducting a Phase 1 clinical study in Kenya to develop TNX-801 as a vaccine to protect against monkeypox and smallpox. The study is expected to start in the first half of 2023.



About TNX-801 and TNX-1850



TNX-801 is a live virus vaccine based on synthesized horsepox2,3. Tonix is developing TNX-801 for percutaneous administration as a vaccine to protect against monkeypox and smallpox. Tonix has previously reported positive data from a monkeypox challenge study in non-human primates4. Tonix is also developing TNX-1850 (horsepox-based live virus vaccines) for the prevention of COVID-19. TNX-1850 is designed to express the spike protein from the BA.2 variants of SARS-CoV-2. Tonix has previously reported positive data from a SARS-CoV-2 challenge study in non-human primates in which animals were vaccinated with TNX-1800, a horsepox-based vaccine expressing spike protein from the Wuhan strain5. Tonix’s TNX-801 was synthesized2&nbsp;based on the sequence of the 1976 natural isolate Mongolian horsepox clone MNR-763. Molecular analysis of DNA sequences suggests that TNX-801 is closer than modern smallpox vaccines to the vaccine discovered and disseminated by Dr. Edward Jenner in 17986-8. For example, recent studies9,10&nbsp;have shown approximately 99.7% colinear identity between TNX-801 and the circa 1860 U.S. smallpox vaccine VK05.11&nbsp;The small plaque size in culture of TNX-801 appears identical to the U.S. Centers for Disease Control publication of the natural isolate12. Relative to vaccinia, horsepox has substantially decreased virulence in mice2. Dr. Edward Jenner invented vaccination in 1798 and the procedure was called “vaccination” because ‘cow’ is ‘vacca’ in Latin and the inoculum material was initially obtained from lesions on the udders of cows affected by a mild disease known as cowpox. However, Dr. Jenner suspected that cowpox originated from horses8. Subsequently, Dr. Jenner and others immunized against smallpox using material directly obtained from horses. The use of vaccines from horses was sometimes called ‘equination’ from the Latin ‘equus’ which means ‘horse’13. Equination and vaccination were practiced side-by-side in Europe13,14.



About the Recombinant Pox Virus (RPV) Platform



Horsepox virus and vaccines based on its use as a vector are live replicating viruses that elicit strong immune responses. Live replicating orthopoxviruses, like vaccinia or horsepox, can be engineered to express foreign genes and have been exploited as platforms for vaccine development because they possess; (1) large packaging capacity for exogenous DNA inserts, (2) precise virus-specific control of exogenous gene insert expression, (3) lack of persistence or genomic integration in the host, (4) strong immunogenicity as a vaccine, (5) ability to rapidly generate vector/insert constructs, (6) manufacturable at scale, and (7) ability to provide direct antigen presentation. Relative to vaccinia, horsepox has substantially decreased virulence in mice2. Horsepox-based vaccines are designed to be single dose, vial-sparing vaccines, that can be manufactured using conventional cell culture systems, with the potential for mass scale production and packaging in multi-dose vials. Tonix’s TNX-801 and RPV vaccine candidates are administered percutaneously using a two-pronged, or “bifurcated” needle. The major cutaneous reaction or “take” to vaccinia vaccine was described by Dr. Edward Jenner in 1796 and has been used since then as a biomarker for protective immunity to smallpox, including in the World Health Organization’s (WHO) accelerated smallpox eradication program that successfully eradicated smallpox in the 1960’s. The “take” is a measure of functional T cell immunity validated by the eradication of smallpox, a respiratory-transmitted disease caused by variola.



About Monkeypox and Smallpox



Monkeypox15&nbsp;and smallpox16&nbsp;are diseases in humans called by the monkeypox and smallpox (or variola) viruses, respectively. Monkeypox and variola are closely related orthopox viruses. Vaccination against smallpox with live virus vaccines based on horsepox or vaccinia protects against monkeypox. After routine smallpox vaccination was stopped in about 1970, monkeypox has become a growing problem in Africa. Recently approximately 300 cases have been identified outside of Africa.17&nbsp;Smallpox is considered eradicated, but there are concerns about malicious reintroduction.



About Tonix Pharmaceuticals Holding Corp.1



Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing therapeutics to treat and prevent human disease and alleviate suffering. Tonix’s portfolio is composed of central nervous system (CNS), rare disease, immunology and infectious disease product candidates. Tonix’s CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Tonix’s lead CNS candidate, TNX-102 SL (cyclobenzaprine HCl sublingual tablet), is in mid-Phase 3 development for the management of fibromyalgia with a new Phase 3 study launched in the second quarter of 2022 and interim data expected in the second quarter of 2023. TNX-102 SL is also being developed to treat Long COVID, a chronic post-acute COVID-19 condition. Tonix initiated a Phase 2 study in Long COVID in the third quarter of 2022 and expects interim data in the second quarter of 2023. TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted Breakthrough Therapy designation by the FDA. A Phase 2 study of TNX-1300 is expected to be initiated in the first quarter of 2023. TNX-1900 (intranasal potentiated oxytocin), a small molecule in development for chronic migraine, is expected to enter the clinic with a Phase 2 study in the first quarter of 2023. TNX-601 ER (tianeptine hemioxalate extended-release tablets) is a once-daily formulation of tianeptine being developed as a potential treatment for major depressive disorder (MDD) with a Phase 2 study expected to be initiated in the first quarter of 2023. Tonix’s rare disease portfolio includes TNX-2900 (intranasal potentiated oxytocin) for the treatment of Prader-Willi syndrome. TNX-2900 has been granted Orphan Drug designation by the FDA. Tonix’s immunology portfolio includes biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. A Phase 1 study of TNX-1500 is expected to be initiated in the first half of 2023. Tonix’s infectious disease pipeline consists of a vaccine in development to prevent smallpox and monkeypox, next-generation vaccines to prevent COVID-19, and a platform to make fully human monoclonal antibodies to treat COVID-19. TNX-801, Tonix’s vaccine in development to prevent smallpox and monkeypox, also serves as the live virus vaccine platform or recombinant pox vaccine (RPV) platform for other infectious diseases. A Phase 1 study of TNX-801 is expected to be initiated in Kenya in the first half of 2023. Tonix’s lead vaccine candidate for COVID-19 is TNX-1850, a live virus vaccines based on Tonix’s recombinant pox live virus vector vaccine platform.



1All of&nbsp;Tonix’s&nbsp;product candidates are investigational new drugs or biologics and have not been approved for any indication.



2Noyce RS, et al. (2018)&nbsp;PLoS&nbsp;One. 13(1):e0188453



3Tulman ER, et al. (2006) J&nbsp;Virol. 80(18):9244-58.PMID:16940536



4Noyce, RS, et al.&nbsp;Synthetic Chimeric Horsepox Virus (scHPXV) Vaccination Protects Macaques from Monkeypox* Presented as a poster at the American Society of Microbiology&nbsp;BioThreats&nbsp;Conference – January 29, 2020, Arlington, VA. (https://content.equisolve.net/tonixpharma/media/10929ac27f4fb5f5204f5cf41d59a121.pdf)



5Tonix Press Release March 16, 202a https://ir.tonixpharma.com/news-events/press-releases/detail/1255/tonix-pharmaceuticals-reports-positive-covid-19-vaccine



6Schrick L et al. N&nbsp;Engl&nbsp;J Med. (2017)&nbsp;377:1491.



7Qin et al. J.&nbsp;Virol.&nbsp;89:1809 (2015).



8Jenner E. “An Inquiry&nbsp;Into&nbsp;the Causes and Effects of the&nbsp;Variolae&nbsp;Vaccinae: A Disease Discovered in Some of the Western Counties of England, Particularly Gloucestershire, and Known by the Name of the Cow Pox.” London: Sampson Low, 1798. 9Brinkmann A et al, Genome Biology (2020) 21:286 https://doi.org/10.1186/s13059-020-02202-0



10Duggan A et al. Genome Biology (2020) 21:175 https://doi.org/10.1186/s13059-020-02079-z



11Tonix press release. Dec 4, 2020 https://ir.tonixpharma.com/news-events/press-releases/detail/1236/vaccine-genome-researchers-report-99-7-colinear-identity



12Trindale GS et al.&nbsp;Viruses&nbsp;(2016) (12).&nbsp;Pii:&nbsp;E328.&nbsp;PMID:27973399



13Esparza E, et al Vaccine. (2017) 35(52):7222-7230.



14Esparza J et al. Vaccine. (2020);&nbsp;38(30):4773-4779.



15www.cdc.gov/poxvirus/monkeypox/about.html



16www.cdc.gov/smallpox/research/



17Mandavilli, A. The New York Times. May 26, 2020. “Who is protected against monkeypox”



This press release and further information about Tonix can be found at&nbsp;<a href="https://www.globenewswire.com/Tracker?data=8b-Jp7UIzO4GKYR5s_Uba-fy6h14tPU3pV5PgEGAS4D7-UazfgbhwCdZVWovbyr3TGZnACa9tgu9lHSifoSzmLshoxqvhGMWl-OeXR8vafU=" target="_blank" rel="noreferrer noopener">www.tonixpharma.com</a>.



Forward Looking Statements



Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; delays and uncertainties caused by the global COVID-19 pandemic; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the Securities and Exchange Commission (the “SEC”) on March 14, 2022, and periodic reports filed with the SEC on or after the date thereof. All of Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.



Contacts



Jessica Morris (corporate) Tonix Pharmaceuticals investor.relations@tonixpharma.com (862) 904-8182



Olipriya Das, Ph.D. (media) Russo Partners Olipriya.Das@russopartnersllc.com (646) 942-5588



Peter Vozzo (investors) ICR Westwicke peter.vozzo@westwicke.com (443) 213-0505



<a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/16aad249-3d33-4501-b3d9-118a703fa46e"></a>



Source: Tonix Pharmaceuticals Holding Corp.



Released December 1, 2022

<div class="wp-block-image">
<figure class="aligncenter size-full is-resized"><img decoding="async" loading="lazy" src="https://dashboard.channelchek.com/wp-content/uploads/2020/10/tnxp_logo.png" alt="" class="wp-image-49291" width="193" height="193" srcset="https://dashboard.channelchek.com/wp-content/uploads/2020/10/tnxp_logo.png 386w, https://dashboard.channelchek.com/wp-content/uploads/2020/10/tnxp_logo-300x300.png 300w, https://dashboard.channelchek.com/wp-content/uploads/2020/10/tnxp_logo-150x150.png 150w" sizes="(max-width: 193px) 100vw, 193px" /></figure></div>


<a href="http://www.channelchek.com/company/tnxp">Research, News, and Market Data on TNXP</a>



December 01, 2022 7:00am EST



TNX-801 is Based on the Sequence of a Natural Isolate of Horsepox and is Believed Closer in Structure to Edward Jenner’s 1798 Vaccine than Modern Vaccinia Virus Vaccines Against Smallpox



Live-Virus Vaccine Platform Leverages Tonix’s Expanding Internal Development and Manufacturing Capabilities for Biologics



CHATHAM, N.J., Dec. 01, 2022 (GLOBE NEWSWIRE) &#8212; Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced that Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, presented data from the Company’s TNX-801 (live horsepox virus vaccine) smallpox and monkeypox vaccine development program in an oral presentation at the World Vaccine and Immunotherapy Congress 2022, being held in San Diego, Calif., November 28 &#8211; December 1, 2022. A copy of the Company’s presentation is available under the&nbsp;<a href="https://www.globenewswire.com/Tracker?data=cMe7ZFL33JzxYoCOdJR95wdprBIDRMShXD7AINhGpmj9atMEZQr2Mu5q-Z9EISUg-gsQcnqAlwyJi2pnpe9SytpSyVIlhwtZa-ltUVuqKmigK9nHrv9M0dAU0yiMLJ7EybOgsD-hsZjXqy5chQoGrQ==" target="_blank" rel="noreferrer noopener">Scientific Presentations</a>&nbsp;tab of the Tonix website at&nbsp;<a href="https://www.globenewswire.com/Tracker?data=8b-Jp7UIzO4GKYR5s_UbaxaxlyWnOu-ZPVF_vp8b40ZoYNVg0UsYCPEH5sH3L9rZVD2u1kkNxV61thEHxFR_fCZWcB2JERyT61s4AflAM3k=" target="_blank" rel="noreferrer noopener">www.tonixpharma.com</a>



“TNX-801 is a live virus vaccine that we believe is closer to the smallpox vaccines used in the U.S. and Europe before 1900 than the modern vaccinia smallpox vaccines. TNX-801 has reduced virulence in animals, and we believe it has the potential for widespread use to protect against monkeypox,” said Seth Lederman, M.D., President and Chief Executive Officer. “Recent global outbreaks of monkeypox have highlighted the need to be prepared with a vaccine that provides durable immunity and blocks forward transmission. Tonix’s live virus vaccine technology is designed to achieve these outcomes.”



The oral presentation titled, “Live Virus Smallpox and Monkeypox Vaccine,” describes the history of live virus vaccines and rationale for the development of the Company’s Recombinant Pox Virus (RPV) platform, including TNX-801 to protect against monkeypox and smallpox. The presentation describes the origins of immunization, beginning with the first live virus vaccine invented by Dr. Edward Jenner in 1798. The inoculation procedure was called “vaccination” and the inoculum material was initially obtained from lesions on cows affected by a mild disease known as cowpox. However, Dr. Jenner suspected that cowpox originated from horses8,which led to immunization using material directly obtained from horses. This procedure was sometimes called “equination”. Equination and vaccination were practiced side-by-side in Europe13,14. Today, molecular analysis of DNA sequences from archaic smallpox vaccines suggests that TNX-801 is closer than modern smallpox vaccinia vaccines to the vaccine discovered and disseminated by Dr. Edward Jenner6-8.



As presented at the Canadian Society for Virology in June 2022, non-human primates vaccinated with TNX-801 were fully protected with sterilizing immunity from a challenge with intra-tracheal monkeypox.



In July 2022, the Company announced a collaboration with the Kenya Medical Research Institute (KEMRI) to seek regulatory approval for conducting a Phase 1 clinical study in Kenya to develop TNX-801 as a vaccine to protect against monkeypox and smallpox. The study is expected to start in the first half of 2023.



About TNX-801 and TNX-1850



TNX-801 is a live virus vaccine based on synthesized horsepox2,3. Tonix is developing TNX-801 for percutaneous administration as a vaccine to protect against monkeypox and smallpox. Tonix has previously reported positive data from a monkeypox challenge study in non-human primates4. Tonix is also developing TNX-1850 (horsepox-based live virus vaccines) for the prevention of COVID-19. TNX-1850 is designed to express the spike protein from the BA.2 variants of SARS-CoV-2. Tonix has previously reported positive data from a SARS-CoV-2 challenge study in non-human primates in which animals were vaccinated with TNX-1800, a horsepox-based vaccine expressing spike protein from the Wuhan strain5. Tonix’s TNX-801 was synthesized2&nbsp;based on the sequence of the 1976 natural isolate Mongolian horsepox clone MNR-763. Molecular analysis of DNA sequences suggests that TNX-801 is closer than modern smallpox vaccines to the vaccine discovered and disseminated by Dr. Edward Jenner in 17986-8. For example, recent studies9,10&nbsp;have shown approximately 99.7% colinear identity between TNX-801 and the circa 1860 U.S. smallpox vaccine VK05.11&nbsp;The small plaque size in culture of TNX-801 appears identical to the U.S. Centers for Disease Control publication of the natural isolate12. Relative to vaccinia, horsepox has substantially decreased virulence in mice2. Dr. Edward Jenner invented vaccination in 1798 and the procedure was called “vaccination” because ‘cow’ is ‘vacca’ in Latin and the inoculum material was initially obtained from lesions on the udders of cows affected by a mild disease known as cowpox. However, Dr. Jenner suspected that cowpox originated from horses8. Subsequently, Dr. Jenner and others immunized against smallpox using material directly obtained from horses. The use of vaccines from horses was sometimes called ‘equination’ from the Latin ‘equus’ which means ‘horse’13. Equination and vaccination were practiced side-by-side in Europe13,14.



About the Recombinant Pox Virus (RPV) Platform



Horsepox virus and vaccines based on its use as a vector are live replicating viruses that elicit strong immune responses. Live replicating orthopoxviruses, like vaccinia or horsepox, can be engineered to express foreign genes and have been exploited as platforms for vaccine development because they possess; (1) large packaging capacity for exogenous DNA inserts, (2) precise virus-specific control of exogenous gene insert expression, (3) lack of persistence or genomic integration in the host, (4) strong immunogenicity as a vaccine, (5) ability to rapidly generate vector/insert constructs, (6) manufacturable at scale, and (7) ability to provide direct antigen presentation. Relative to vaccinia, horsepox has substantially decreased virulence in mice2. Horsepox-based vaccines are designed to be single dose, vial-sparing vaccines, that can be manufactured using conventional cell culture systems, with the potential for mass scale production and packaging in multi-dose vials. Tonix’s TNX-801 and RPV vaccine candidates are administered percutaneously using a two-pronged, or “bifurcated” needle. The major cutaneous reaction or “take” to vaccinia vaccine was described by Dr. Edward Jenner in 1796 and has been used since then as a biomarker for protective immunity to smallpox, including in the World Health Organization’s (WHO) accelerated smallpox eradication program that successfully eradicated smallpox in the 1960’s. The “take” is a measure of functional T cell immunity validated by the eradication of smallpox, a respiratory-transmitted disease caused by variola.



About Monkeypox and Smallpox



Monkeypox15&nbsp;and smallpox16&nbsp;are diseases in humans called by the monkeypox and smallpox (or variola) viruses, respectively. Monkeypox and variola are closely related orthopox viruses. Vaccination against smallpox with live virus vaccines based on horsepox or vaccinia protects against monkeypox. After routine smallpox vaccination was stopped in about 1970, monkeypox has become a growing problem in Africa. Recently approximately 300 cases have been identified outside of Africa.17&nbsp;Smallpox is considered eradicated, but there are concerns about malicious reintroduction.



About Tonix Pharmaceuticals Holding Corp.1



Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing therapeutics to treat and prevent human disease and alleviate suffering. Tonix’s portfolio is composed of central nervous system (CNS), rare disease, immunology and infectious disease product candidates. Tonix’s CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Tonix’s lead CNS candidate, TNX-102 SL (cyclobenzaprine HCl sublingual tablet), is in mid-Phase 3 development for the management of fibromyalgia with a new Phase 3 study launched in the second quarter of 2022 and interim data expected in the second quarter of 2023. TNX-102 SL is also being developed to treat Long COVID, a chronic post-acute COVID-19 condition. Tonix initiated a Phase 2 study in Long COVID in the third quarter of 2022 and expects interim data in the second quarter of 2023. TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted Breakthrough Therapy designation by the FDA. A Phase 2 study of TNX-1300 is expected to be initiated in the first quarter of 2023. TNX-1900 (intranasal potentiated oxytocin), a small molecule in development for chronic migraine, is expected to enter the clinic with a Phase 2 study in the first quarter of 2023. TNX-601 ER (tianeptine hemioxalate extended-release tablets) is a once-daily formulation of tianeptine being developed as a potential treatment for major depressive disorder (MDD) with a Phase 2 study expected to be initiated in the first quarter of 2023. Tonix’s rare disease portfolio includes TNX-2900 (intranasal potentiated oxytocin) for the treatment of Prader-Willi syndrome. TNX-2900 has been granted Orphan Drug designation by the FDA. Tonix’s immunology portfolio includes biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. A Phase 1 study of TNX-1500 is expected to be initiated in the first half of 2023. Tonix’s infectious disease pipeline consists of a vaccine in development to prevent smallpox and monkeypox, next-generation vaccines to prevent COVID-19, and a platform to make fully human monoclonal antibodies to treat COVID-19. TNX-801, Tonix’s vaccine in development to prevent smallpox and monkeypox, also serves as the live virus vaccine platform or recombinant pox vaccine (RPV) platform for other infectious diseases. A Phase 1 study of TNX-801 is expected to be initiated in Kenya in the first half of 2023. Tonix’s lead vaccine candidate for COVID-19 is TNX-1850, a live virus vaccines based on Tonix’s recombinant pox live virus vector vaccine platform.



1All of&nbsp;Tonix’s&nbsp;product candidates are investigational new drugs or biologics and have not been approved for any indication.



2Noyce RS, et al. (2018)&nbsp;PLoS&nbsp;One. 13(1):e0188453



3Tulman ER, et al. (2006) J&nbsp;Virol. 80(18):9244-58.PMID:16940536



4Noyce, RS, et al.&nbsp;Synthetic Chimeric Horsepox Virus (scHPXV) Vaccination Protects Macaques from Monkeypox* Presented as a poster at the American Society of Microbiology&nbsp;BioThreats&nbsp;Conference – January 29, 2020, Arlington, VA. (https://content.equisolve.net/tonixpharma/media/10929ac27f4fb5f5204f5cf41d59a121.pdf)



5Tonix Press Release March 16, 202a https://ir.tonixpharma.com/news-events/press-releases/detail/1255/tonix-pharmaceuticals-reports-positive-covid-19-vaccine



6Schrick L et al. N&nbsp;Engl&nbsp;J Med. (2017)&nbsp;377:1491.



7Qin et al. J.&nbsp;Virol.&nbsp;89:1809 (2015).



8Jenner E. “An Inquiry&nbsp;Into&nbsp;the Causes and Effects of the&nbsp;Variolae&nbsp;Vaccinae: A Disease Discovered in Some of the Western Counties of England, Particularly Gloucestershire, and Known by the Name of the Cow Pox.” London: Sampson Low, 1798. 9Brinkmann A et al, Genome Biology (2020) 21:286 https://doi.org/10.1186/s13059-020-02202-0



10Duggan A et al. Genome Biology (2020) 21:175 https://doi.org/10.1186/s13059-020-02079-z



11Tonix press release. Dec 4, 2020 https://ir.tonixpharma.com/news-events/press-releases/detail/1236/vaccine-genome-researchers-report-99-7-colinear-identity



12Trindale GS et al.&nbsp;Viruses&nbsp;(2016) (12).&nbsp;Pii:&nbsp;E328.&nbsp;PMID:27973399



13Esparza E, et al Vaccine. (2017) 35(52):7222-7230.



14Esparza J et al. Vaccine. (2020);&nbsp;38(30):4773-4779.



15www.cdc.gov/poxvirus/monkeypox/about.html



16www.cdc.gov/smallpox/research/



17Mandavilli, A. The New York Times. May 26, 2020. “Who is protected against monkeypox”



This press release and further information about Tonix can be found at&nbsp;<a href="https://www.globenewswire.com/Tracker?data=8b-Jp7UIzO4GKYR5s_Uba-fy6h14tPU3pV5PgEGAS4D7-UazfgbhwCdZVWovbyr3TGZnACa9tgu9lHSifoSzmLshoxqvhGMWl-OeXR8vafU=" target="_blank" rel="noreferrer noopener">www.tonixpharma.com</a>.



Forward Looking Statements



Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix&#8217;s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; delays and uncertainties caused by the global COVID-19 pandemic; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the Securities and Exchange Commission (the “SEC”) on March 14, 2022, and periodic reports filed with the SEC on or after the date thereof. All of Tonix&#8217;s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.



Contacts



Jessica Morris (corporate) Tonix Pharmaceuticals investor.relations@tonixpharma.com (862) 904-8182



Olipriya Das, Ph.D. (media) Russo Partners Olipriya.Das@russopartnersllc.com (646) 942-5588



Peter Vozzo (investors) ICR Westwicke peter.vozzo@westwicke.com (443) 213-0505



<a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/16aad249-3d33-4501-b3d9-118a703fa46e"></a>



Source: Tonix Pharmaceuticals Holding Corp.



Released December 1, 2022

Research, News, and Market Data on TNXP



December 01, 2022 7:00am EST



TNX-801 is Based on the Sequence of a Natural Isolate of Horsepox and is Believed Closer in Structure to Edward Jenner’s 1798 Vaccine than Modern Vaccinia Virus Vaccines Against Smallpox



Live-Virus Vaccine Platform Leverages Tonix’s Expanding Internal Development and Manufacturing Capabilities for Biologics



CHATHAM, N.J., Dec. 01, 2022 (GLOBE NEWSWIRE) &#8212; Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceutical company, today announced that Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals, presented data from the Company’s TNX-801 (live horsepox virus vaccine) smallpox and monkeypox vaccine development program in an oral presentation at the World Vaccine and Immunotherapy Congress 2022, being held in San Diego, Calif., November 28 &#8211; December 1, 2022. A copy of the Company’s presentation is available under the&nbsp;Scientific Presentations&nbsp;tab of the Tonix website at&nbsp;www.tonixpharma.com



“TNX-801 is a live virus vaccine that we believe is closer to the smallpox vaccines used in the U.S. and Europe before 1900 than the modern vaccinia smallpox vaccines. TNX-801 has reduced virulence in animals, and we believe it has the potential for widespread use to protect against monkeypox,” said Seth Lederman, M.D., President and Chief Executive Officer. “Recent global outbreaks of monkeypox have highlighted the need to be prepared with a vaccine that provides durable immunity and blocks forward transmission. Tonix’s live virus vaccine technology is designed to achieve these outcomes.”



The oral presentation titled, “Live Virus Smallpox and Monkeypox Vaccine,” describes the history of live virus vaccines and rationale for the development of the Company’s Recombinant Pox Virus (RPV) platform, including TNX-801 to protect against monkeypox and smallpox. The presentation describes the origins of immunization, beginning with the first live virus vaccine invented by Dr. Edward Jenner in 1798. The inoculation procedure was called “vaccination” and the inoculum material was initially obtained from lesions on cows affected by a mild disease known as cowpox. However, Dr. Jenner suspected that cowpox originated from horses8,which led to immunization using material directly obtained from horses. This procedure was sometimes called “equination”. Equination and vaccination were practiced side-by-side in Europe13,14. Today, molecular analysis of DNA sequences from archaic smallpox vaccines suggests that TNX-801 is closer than modern smallpox vaccinia vaccines to the vaccine discovered and disseminated by Dr. Edward Jenner6-8.



As presented at the Canadian Society for Virology in June 2022, non-human primates vaccinated with TNX-801 were fully protected with sterilizing immunity from a challenge with intra-tracheal monkeypox.



In July 2022, the Company announced a collaboration with the Kenya Medical Research Institute (KEMRI) to seek regulatory approval for conducting a Phase 1 clinical study in Kenya to develop TNX-801 as a vaccine to protect against monkeypox and smallpox. The study is expected to start in the first half of 2023.



About TNX-801 and TNX-1850



TNX-801 is a live virus vaccine based on synthesized horsepox2,3. Tonix is developing TNX-801 for percutaneous administration as a vaccine to protect against monkeypox and smallpox. Tonix has previously reported positive data from a monkeypox challenge study in non-human primates4. Tonix is also developing TNX-1850 (horsepox-based live virus vaccines) for the prevention of COVID-19. TNX-1850 is designed to express the spike protein from the BA.2 variants of SARS-CoV-2. Tonix has previously reported positive data from a SARS-CoV-2 challenge study in non-human primates in which animals were vaccinated with TNX-1800, a horsepox-based vaccine expressing spike protein from the Wuhan strain5. Tonix’s TNX-801 was synthesized2&nbsp;based on the sequence of the 1976 natural isolate Mongolian horsepox clone MNR-763. Molecular analysis of DNA sequences suggests that TNX-801 is closer than modern smallpox vaccines to the vaccine discovered and disseminated by Dr. Edward Jenner in 17986-8. For example, recent studies9,10&nbsp;have shown approximately 99.7% colinear identity between TNX-801 and the circa 1860 U.S. smallpox vaccine VK05.11&nbsp;The small plaque size in culture of TNX-801 appears identical to the U.S. Centers for Disease Control publication of the natural isolate12. Relative to vaccinia, horsepox has substantially decreased virulence in mice2. Dr. Edward Jenner invented vaccination in 1798 and the procedure was called “vaccination” because ‘cow’ is ‘vacca’ in Latin and the inoculum material was initially obtained from lesions on the udders of cows affected by a mild disease known as cowpox. However, Dr. Jenner suspected that cowpox originated from horses8. Subsequently, Dr. Jenner and others immunized against smallpox using material directly obtained from horses. The use of vaccines from horses was sometimes called ‘equination’ from the Latin ‘equus’ which means ‘horse’13. Equination and vaccination were practiced side-by-side in Europe13,14.



About the Recombinant Pox Virus (RPV) Platform



Horsepox virus and vaccines based on its use as a vector are live replicating viruses that elicit strong immune responses. Live replicating orthopoxviruses, like vaccinia or horsepox, can be engineered to express foreign genes and have been exploited as platforms for vaccine development because they possess; (1) large packaging capacity for exogenous DNA inserts, (2) precise virus-specific control of exogenous gene insert expression, (3) lack of persistence or genomic integration in the host, (4) strong immunogenicity as a vaccine, (5) ability to rapidly generate vector/insert constructs, (6) manufacturable at scale, and (7) ability to provide direct antigen presentation. Relative to vaccinia, horsepox has substantially decreased virulence in mice2. Horsepox-based vaccines are designed to be single dose, vial-sparing vaccines, that can be manufactured using conventional cell culture systems, with the potential for mass scale production and packaging in multi-dose vials. Tonix’s TNX-801 and RPV vaccine candidates are administered percutaneously using a two-pronged, or “bifurcated” needle. The major cutaneous reaction or “take” to vaccinia vaccine was described by Dr. Edward Jenner in 1796 and has been used since then as a biomarker for protective immunity to smallpox, including in the World Health Organization’s (WHO) accelerated smallpox eradication program that successfully eradicated smallpox in the 1960’s. The “take” is a measure of functional T cell immunity validated by the eradication of smallpox, a respiratory-transmitted disease caused by variola.



About Monkeypox and Smallpox



Monkeypox15&nbsp;and smallpox16&nbsp;are diseases in humans called by the monkeypox and smallpox (or variola) viruses, respectively. Monkeypox and variola are closely related orthopox viruses. Vaccination against smallpox with live virus vaccines based on horsepox or vaccinia protects against monkeypox. After routine smallpox vaccination was stopped in about 1970, monkeypox has become a growing problem in Africa. Recently approximately 300 cases have been identified outside of Africa.17&nbsp;Smallpox is considered eradicated, but there are concerns about malicious reintroduction.



About Tonix Pharmaceuticals Holding Corp.1



Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing therapeutics to treat and prevent human disease and alleviate suffering. Tonix’s portfolio is composed of central nervous system (CNS), rare disease, immunology and infectious disease product candidates. Tonix’s CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Tonix’s lead CNS candidate, TNX-102 SL (cyclobenzaprine HCl sublingual tablet), is in mid-Phase 3 development for the management of fibromyalgia with a new Phase 3 study launched in the second quarter of 2022 and interim data expected in the second quarter of 2023. TNX-102 SL is also being developed to treat Long COVID, a chronic post-acute COVID-19 condition. Tonix initiated a Phase 2 study in Long COVID in the third quarter of 2022 and expects interim data in the second quarter of 2023. TNX-1300 (cocaine esterase) is a biologic designed to treat cocaine intoxication and has been granted Breakthrough Therapy designation by the FDA. A Phase 2 study of TNX-1300 is expected to be initiated in the first quarter of 2023. TNX-1900 (intranasal potentiated oxytocin), a small molecule in development for chronic migraine, is expected to enter the clinic with a Phase 2 study in the first quarter of 2023. TNX-601 ER (tianeptine hemioxalate extended-release tablets) is a once-daily formulation of tianeptine being developed as a potential treatment for major depressive disorder (MDD) with a Phase 2 study expected to be initiated in the first quarter of 2023. Tonix’s rare disease portfolio includes TNX-2900 (intranasal potentiated oxytocin) for the treatment of Prader-Willi syndrome. TNX-2900 has been granted Orphan Drug designation by the FDA. Tonix’s immunology portfolio includes biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. A Phase 1 study of TNX-1500 is expected to be initiated in the first half of 2023. Tonix’s infectious disease pipeline consists of a vaccine in development to prevent smallpox and monkeypox, next-generation vaccines to prevent COVID-19, and a platform to make fully human monoclonal antibodies to treat COVID-19. TNX-801, Tonix’s vaccine in development to prevent smallpox and monkeypox, also serves as the live virus vaccine platform or recombinant pox vaccine (RPV) platform for other infectious diseases. A Phase 1 study of TNX-801 is expected to be initiated in Kenya in the first half of 2023. Tonix’s lead vaccine candidate for COVID-19 is TNX-1850, a live virus vaccines based on Tonix’s recombinant pox live virus vector vaccine platform.



1All of&nbsp;Tonix’s&nbsp;product candidates are investigational new drugs or biologics and have not been approved for any indication.



2Noyce RS, et al. (2018)&nbsp;PLoS&nbsp;One. 13(1):e0188453



3Tulman ER, et al. (2006) J&nbsp;Virol. 80(18):9244-58.PMID:16940536



4Noyce, RS, et al.&nbsp;Synthetic Chimeric Horsepox Virus (scHPXV) Vaccination Protects Macaques from Monkeypox* Presented as a poster at the American Society of Microbiology&nbsp;BioThreats&nbsp;Conference – January 29, 2020, Arlington, VA. (https://content.equisolve.net/tonixpharma/media/10929ac27f4fb5f5204f5cf41d59a121.pdf)



5Tonix Press Release March 16, 202a https://ir.tonixpharma.com/news-events/press-releases/detail/1255/tonix-pharmaceuticals-reports-positive-covid-19-vaccine



6Schrick L et al. N&nbsp;Engl&nbsp;J Med. (2017)&nbsp;377:1491.



7Qin et al. J.&nbsp;Virol.&nbsp;89:1809 (2015).



8Jenner E. “An Inquiry&nbsp;Into&nbsp;the Causes and Effects of the&nbsp;Variolae&nbsp;Vaccinae: A Disease Discovered in Some of the Western Counties of England, Particularly Gloucestershire, and Known by the Name of the Cow Pox.” London: Sampson Low, 1798.9Brinkmann A et al, Genome Biology (2020) 21:286 https://doi.org/10.1186/s13059-020-02202-0



10Duggan A et al. Genome Biology (2020) 21:175 https://doi.org/10.1186/s13059-020-02079-z



11Tonix press release. Dec 4, 2020 https://ir.tonixpharma.com/news-events/press-releases/detail/1236/vaccine-genome-researchers-report-99-7-colinear-identity



12Trindale GS et al.&nbsp;Viruses&nbsp;(2016) (12).&nbsp;Pii:&nbsp;E328.&nbsp;PMID:27973399



13Esparza E, et al Vaccine. (2017) 35(52):7222-7230.



14Esparza J et al. Vaccine. (2020);&nbsp;38(30):4773-4779.



15www.cdc.gov/poxvirus/monkeypox/about.html



16www.cdc.gov/smallpox/research/



17Mandavilli, A. The New York Times. May 26, 2020. “Who is protected against monkeypox”



This press release and further information about Tonix can be found at&nbsp;www.tonixpharma.com.



Forward Looking Statements



Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix&#8217;s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; delays and uncertainties caused by the global COVID-19 pandemic; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the Securities and Exchange Commission (the “SEC”) on March 14, 2022, and periodic reports filed with the SEC on or after the date thereof. All of Tonix&#8217;s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.



Contacts



Jessica Morris (corporate)Tonix Pharmaceuticalsinvestor.relations@tonixpharma.com(862) 904-8182



Olipriya Das, Ph.D. (media)Russo PartnersOlipriya.Das@russopartnersllc.com(646) 942-5588



Peter Vozzo (investors)ICR Westwickepeter.vozzo@westwicke.com(443) 213-0505







Source: Tonix Pharmaceuticals Holding Corp.



Released December 1, 2022

Release - Tonix Pharmaceuticals Presents Development Update on Potential Smallpox and Monkeypox Vaccine TNX-801 in an Oral Presentation at the World Vaccine and Immunotherapy Congress

Biopharmaceutical

TNXP

Tonix Pharmaceuticals Holding Corp.

<figure class="wp-block-image aligncenter size-full is-resized"><img src="https://dashboard.channelchek.com/wp-content/uploads/2022/09/lode-logo-pr.png" alt="" class="wp-image-49690" width="271" height="58"/></figure>



<a href="http://www.channelchek.com/company/lode">Research, News, and Market Data on LODE</a>



VIRGINIA CITY, Nev., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Comstock Inc. (NYSE: LODE) (“Comstock” or the “Company”) today announced the publication of the initial technical report for the Company’s Dayton Consolidated Project. Behre Dolbear authored the independent, initial assessment of the Dayton Consolidated Project mineral resources, as of November 1, 2022, compliant with current SEC S-K 1300 guidelines. The full report is available on the Company’s website, at&nbsp;<a href="https://www.globenewswire.com/Tracker?data=KpIaWOIrne4gUDbNYO_a6oK63GYMpVlpv7YmBY8mFHLMxedAOU0XKmhw3wq0713VyvLdsoxPrcuMjWBr6md3l0ozgvSSkDbxRs12z4BhWQ8=" target="_blank" rel="noreferrer noopener">www.comstock.inc/investors</a>.



The estimated mineral resource is constrained within an open pit economic shell based on a gold price of $1,800 per ounce and reported at a cutoff grade of 0.007 ounce gold per ton. The estimate includes Measured and Indicated resources containing 293,000 ounces of gold and 2,120,000 ounces of silver, plus an additional Inferred resource containing 90,000 ounces of gold and 480,000 ounces of silver.



<figure class="wp-block-image size-large"><img src="https://dashboard.channelchek.com/wp-content/uploads/2022/12/lode-1024x221.png" alt="" class="wp-image-53396"/></figure>



The Dayton resource is located approximately one mile south of the Company’s Lucerne mining area, along State Route&nbsp;342 and State Route 341. It includes the historic Dayton, Alhambra, Metropolitan, and Kossuth mines. Additional Comstock exploration areas located northwest, southwest, and south of the Dayton Project include Oest, Amazon Extension of Oest, and Spring Valley, respectively.



The Dayton project has long been known for high grade assays, with gold assays as high as 2.95 ounces per ton, and silver assays as high as 6.68 ounces per ton. Drilling by Comstock has also encountered significant thicknesses of mineralization, including 135 feet averaging 0.218 ounces per ton Au and 0.685 ounces per ton Ag (hole D11-21), 145 feet averaging 0.056 ounces per ton Au and 0.352 ounces per ton Ag (hole D11-33), 50 feet averaging 0.030 ounces per ton Au and 1.072 ounces per ton Ag (hole D94-17), 295 feet averaging 0.027 ounces per ton Au and 0.087 ounces per ton Ag (hole D10-01), and 235 feet averaging 0.031 ounces per ton Au and 0.102 ounces per ton Ag (hole SV12-05).



The report reflects a newly developed geologic model based on highly detailed and methodical identification and correlation of structural and lithological controls for mineralization.



Behre Dolbear’s conclusions include,



<ul>
<li>The Dayton Project represents an early stage but well-explored, epithermal, precious metal deposit within an historic world-class mining district.</li>



<li>The geology of the project area, particularly in the Dayton resource area, is well described and understood through vigorous surface and underground mapping and drill hole logging.</li>



<li>Based upon drilling, continuity of the mineralized zone appears to be good.</li>



<li>The QP opines that potentially higher-grade mineralization may exist in previously un-drilled areas in the Dayton resource where northeast striking faults intersect.</li>



<li>The deposit is hosted in structurally prepared rocks within the southerly striking east dipping Silver City fault zone extension. Grades and extent of mineralization are enhanced where this fault zone is intersected by north-south, northwest, and northeast striking faults and in particular where N50°E faults intersect N75°E faults.</li>



<li>At Spring Valley, high-grade or bonanza-style mineralization may be present as much of the area is covered by post-mineral gravel and historic mining is minimal.</li>
</ul>



“These results confirm the quality and growth potential of our Dayton resource,” stated Corrado De Gasperis, Comstock’s Executive Chairman and CEO. “When combined with the results of the recent technical report published on our Lucerne resource, Comstock controls significant, district-wide mineral resources with outstanding potential for further gold and silver mineral resource growth.”



Comstock plans to develop the Dayton resource systemically, through the deployment of more advanced mineral discovery technologies and a series of phased drilling programs and engineering studies. A first phase of drilling, recommended by Behre Dolbear, includes 70 RC holes totaling 31,500 feet that will, among other objectives, test for high grade mineralization and step out exploration into Spring Valley.



About Behre Dolbear Behre Dolbear is a one of the oldest mineral industry advisory firms in the world, continuously operating since 1911. Behre Dolbear authored the&nbsp;Technical Report Summary, Dayton Consolidated Project, Lyon County, Nevada&nbsp;as an independent third-party, following the United States Security and Exchange Commission’s mining rules under subpart 1300 of Regulation S-K.



About Comstock Comstock (NYSE: LODE) innovates technologies that contribute to global decarbonization and circularity by efficiently converting under-utilized natural resources into renewable fuels and electrification products that contribute to balancing global uses and emissions of carbon. The Company intends to achieve exponential growth and extraordinary financial, natural, and social gains by building, owning, and operating a fleet of advanced carbon neutral extraction and refining facilities, by selling an array of complementary process solutions and related services, and by licensing selected technologies to qualified strategic partners. To learn more, please visit&nbsp;<a href="https://www.globenewswire.com/Tracker?data=KpIaWOIrne4gUDbNYO_a6onpTbxXhtMgbBBlkYNcZjqp0GGov7Pzoonh08wEVAPYCJ4ep_m_nFLqJzEOE_7hzA==" target="_blank" rel="noreferrer noopener">www.comstock.inc</a>.



Forward-Looking Statements&nbsp; This press release and any related calls or discussions may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, are forward-looking statements. The words “believe,” “expect,” “anticipate,” “estimate,” “project,” “plan,” “should,” “intend,” “may,” “will,” “would,” “potential” and similar expressions identify forward-looking statements but are not the exclusive means of doing so. Forward-looking statements include statements about matters such as: future industry market conditions; future explorations or acquisitions; future changes in our exploration activities; future prices and sales of, and demand for, our products; land entitlements and uses; permits; production capacity and operations; operating and overhead costs; future capital expenditures and their impact on us; operational and management changes (including changes in the Board of Directors); changes in business strategies, planning and tactics; future employment and contributions of personnel, including consultants; future land sales; investments, acquisitions, joint ventures, strategic alliances, business combinations, operational, tax, financial and restructuring initiatives, including the nature, timing and accounting for restructuring charges, derivative assets and liabilities and the impact thereof; contingencies; litigation, administrative or arbitration proceedings; environmental compliance and changes in the regulatory environment; offerings, limitations on sales or offering of equity or debt securities, including asset sales and associated costs; and future working capital, costs, revenues, business opportunities, debt levels, cash flows, margins, taxes, earnings and growth. These statements are based on assumptions and assessments made by our management considering their experience and their perception of historical and current trends, current conditions, possible future developments, and other factors they believe to be appropriate. Forward-looking statements are not guarantees, representations or warranties and are subject to risks and uncertainties, many of which are unforeseeable and beyond our control and could cause actual results, developments, and business decisions to differ materially from those contemplated by such forward-looking statements. Some of those risks and uncertainties include the risk factors set forth in our filings with the SEC and the following: adverse effects of climate changes or natural disasters; adverse effects of global or regional pandemic disease spread or other crises; global economic and capital market uncertainties; the speculative nature of gold or mineral exploration, and lithium, nickel and cobalt recycling, including risks of diminishing quantities or grades of qualified resources; metal recycling, processing or mining activities; costs, hazards and uncertainties associated with precious metal based activities, including environmentally friendly and economically enhancing clean mining and processing technologies, precious metal exploration, resource development, economic feasibility assessment and cash generating mineral production; costs, hazards and uncertainties associated with metal recycling, processing or mining activities; contests over our title to properties; potential dilution to our stockholders from our stock issuances, recapitalization and balance sheet restructuring activities; potential inability to comply with applicable government regulations or law; adoption of or changes in legislation or regulations adversely affecting our businesses; permitting constraints or delays; ability to achieve the benefits of business opportunities that may be presented to, or pursued by, us, including those involving battery technology, quantum computing and advanced materials development, and development of cellulosic technology in bio-fuels and related carbon-based material production; ability to successfully identify, finance, complete and integrate acquisitions, joint ventures, strategic alliances, business combinations, asset sales, and investments that we may be party to in the future; changes in the United States or other monetary or fiscal policies or regulations; interruptions in our production capabilities due to capital constraints; equipment failures; fluctuation of prices for gold or certain other commodities (such as silver, zinc, lithium, nickel, cobalt, cyanide, water, diesel, gasoline and alternative fuels and electricity); changes in generally accepted accounting principles; adverse effects of war, mass shooting, terrorism and geopolitical events; potential inability to implement our business strategies; potential inability to grow revenues; potential inability to attract and retain key personnel; interruptions in delivery of critical supplies, equipment and raw materials due to credit or other limitations imposed by vendors; assertion of claims, lawsuits and proceedings against us; potential inability to satisfy debt and lease obligations; potential inability to maintain an effective system of internal controls over financial reporting; potential inability or failure to timely file periodic reports with the Securities and Exchange Commission; potential inability to list our securities on any securities exchange or market or maintain the listing of our securities; and work stoppages or other labor difficulties. Occurrence of such events or circumstances could have a material adverse effect on our business, financial condition, results of operations or cash flows, or the market price of our securities. All subsequent written and oral forward-looking statements by or attributable to us or persons acting on our behalf are expressly qualified in their entirety by these factors. Except as may be required by securities or other law, we undertake no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise.



Neither this press release nor any related calls or discussions constitutes an offer to sell, the solicitation of an offer to buy or a recommendation with respect to any securities of the Company, the fund, or any other issuer.



Contact information:



<figure class="wp-block-table"><table><tbody><tr><td>Comstock Inc. P.O. Box 1118 Virginia City, NV 89440 www.comstock.inc</td><td>Corrado De Gasperis Executive Chairman &amp; CEO Tel (775) 847-4755 degasperis@comstockinc.com</td><td>Zach Spencer Director of External Relations Tel (775) 847-5272 Ext.151 questions@comstockinc.com</td></tr></tbody></table></figure>

<div class="wp-block-image">
<figure class="aligncenter size-full is-resized"><img decoding="async" loading="lazy" src="https://dashboard.channelchek.com/wp-content/uploads/2022/09/lode-logo-pr.png" alt="" class="wp-image-49690" width="271" height="58" srcset="https://dashboard.channelchek.com/wp-content/uploads/2022/09/lode-logo-pr.png 321w, https://dashboard.channelchek.com/wp-content/uploads/2022/09/lode-logo-pr-300x64.png 300w" sizes="(max-width: 271px) 100vw, 271px" /></figure></div>


<a href="http://www.channelchek.com/company/lode">Research, News, and Market Data on LODE</a>



VIRGINIA CITY, Nev., Dec. 01, 2022 (GLOBE NEWSWIRE) &#8212; Comstock Inc. (NYSE: LODE) (“Comstock” or the “Company”) today announced the publication of the initial technical report for the Company’s Dayton Consolidated Project. Behre Dolbear authored the independent, initial assessment of the Dayton Consolidated Project mineral resources, as of November 1, 2022, compliant with current SEC S-K 1300 guidelines. The full report is available on the Company’s website, at&nbsp;<a href="https://www.globenewswire.com/Tracker?data=KpIaWOIrne4gUDbNYO_a6oK63GYMpVlpv7YmBY8mFHLMxedAOU0XKmhw3wq0713VyvLdsoxPrcuMjWBr6md3l0ozgvSSkDbxRs12z4BhWQ8=" target="_blank" rel="noreferrer noopener">www.comstock.inc/investors</a>.



The estimated mineral resource is constrained within an open pit economic shell based on a gold price of $1,800 per ounce and reported at a cutoff grade of 0.007 ounce gold per ton. The estimate includes Measured and Indicated resources containing 293,000 ounces of gold and 2,120,000 ounces of silver, plus an additional Inferred resource containing 90,000 ounces of gold and 480,000 ounces of silver.



<figure class="wp-block-image size-large"><img decoding="async" loading="lazy" width="1024" height="221" src="https://dashboard.channelchek.com/wp-content/uploads/2022/12/lode-1024x221.png" alt="" class="wp-image-53396" srcset="https://dashboard.channelchek.com/wp-content/uploads/2022/12/lode-1024x221.png 1024w, https://dashboard.channelchek.com/wp-content/uploads/2022/12/lode-300x65.png 300w, https://dashboard.channelchek.com/wp-content/uploads/2022/12/lode-768x166.png 768w, https://dashboard.channelchek.com/wp-content/uploads/2022/12/lode-1536x332.png 1536w, https://dashboard.channelchek.com/wp-content/uploads/2022/12/lode.png 1831w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>



The Dayton resource is located approximately one mile south of the Company’s Lucerne mining area, along State Route&nbsp;342 and State Route 341. It includes the historic Dayton, Alhambra, Metropolitan, and Kossuth mines. Additional Comstock exploration areas located northwest, southwest, and south of the Dayton Project include Oest, Amazon Extension of Oest, and Spring Valley, respectively.



The Dayton project has long been known for high grade assays, with gold assays as high as 2.95 ounces per ton, and silver assays as high as 6.68 ounces per ton. Drilling by Comstock has also encountered significant thicknesses of mineralization, including 135 feet averaging 0.218 ounces per ton Au and 0.685 ounces per ton Ag (hole D11-21), 145 feet averaging 0.056 ounces per ton Au and 0.352 ounces per ton Ag (hole D11-33), 50 feet averaging 0.030 ounces per ton Au and 1.072 ounces per ton Ag (hole D94-17), 295 feet averaging 0.027 ounces per ton Au and 0.087 ounces per ton Ag (hole D10-01), and 235 feet averaging 0.031 ounces per ton Au and 0.102 ounces per ton Ag (hole SV12-05).



The report reflects a newly developed geologic model based on highly detailed and methodical identification and correlation of structural and lithological controls for mineralization.



Behre Dolbear’s conclusions include,



<ul>
<li>The Dayton Project represents an early stage but well-explored, epithermal, precious metal deposit within an historic world-class mining district.</li>



<li>The geology of the project area, particularly in the Dayton resource area, is well described and understood through vigorous surface and underground mapping and drill hole logging.</li>



<li>Based upon drilling, continuity of the mineralized zone appears to be good.</li>



<li>The QP opines that potentially higher-grade mineralization may exist in previously un-drilled areas in the Dayton resource where northeast striking faults intersect.</li>



<li>The deposit is hosted in structurally prepared rocks within the southerly striking east dipping Silver City fault zone extension. Grades and extent of mineralization are enhanced where this fault zone is intersected by north-south, northwest, and northeast striking faults and in particular where N50°E faults intersect N75°E faults.</li>



<li>At Spring Valley, high-grade or bonanza-style mineralization may be present as much of the area is covered by post-mineral gravel and historic mining is minimal.</li>
</ul>



“These results confirm the quality and growth potential of our Dayton resource,” stated Corrado De Gasperis, Comstock’s Executive Chairman and CEO. “When combined with the results of the recent technical report published on our Lucerne resource, Comstock controls significant, district-wide mineral resources with outstanding potential for further gold and silver mineral resource growth.”



Comstock plans to develop the Dayton resource systemically, through the deployment of more advanced mineral discovery technologies and a series of phased drilling programs and engineering studies. A first phase of drilling, recommended by Behre Dolbear, includes 70 RC holes totaling 31,500 feet that will, among other objectives, test for high grade mineralization and step out exploration into Spring Valley.



About Behre Dolbear Behre Dolbear is a one of the oldest mineral industry advisory firms in the world, continuously operating since 1911. Behre Dolbear authored the&nbsp;Technical Report Summary, Dayton Consolidated Project, Lyon County, Nevada&nbsp;as an independent third-party, following the United States Security and Exchange Commission’s mining rules under subpart 1300 of Regulation S-K.



About Comstock Comstock (NYSE: LODE) innovates technologies that contribute to global decarbonization and circularity by efficiently converting under-utilized natural resources into renewable fuels and electrification products that contribute to balancing global uses and emissions of carbon. The Company intends to achieve exponential growth and extraordinary financial, natural, and social gains by building, owning, and operating a fleet of advanced carbon neutral extraction and refining facilities, by selling an array of complementary process solutions and related services, and by licensing selected technologies to qualified strategic partners. To learn more, please visit&nbsp;<a href="https://www.globenewswire.com/Tracker?data=KpIaWOIrne4gUDbNYO_a6onpTbxXhtMgbBBlkYNcZjqp0GGov7Pzoonh08wEVAPYCJ4ep_m_nFLqJzEOE_7hzA==" target="_blank" rel="noreferrer noopener">www.comstock.inc</a>.



Forward-Looking Statements&nbsp; This press release and any related calls or discussions may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, are forward-looking statements. The words “believe,” “expect,” “anticipate,” “estimate,” “project,” “plan,” “should,” “intend,” “may,” “will,” “would,” “potential” and similar expressions identify forward-looking statements but are not the exclusive means of doing so. Forward-looking statements include statements about matters such as: future industry market conditions; future explorations or acquisitions; future changes in our exploration activities; future prices and sales of, and demand for, our products; land entitlements and uses; permits; production capacity and operations; operating and overhead costs; future capital expenditures and their impact on us; operational and management changes (including changes in the Board of Directors); changes in business strategies, planning and tactics; future employment and contributions of personnel, including consultants; future land sales; investments, acquisitions, joint ventures, strategic alliances, business combinations, operational, tax, financial and restructuring initiatives, including the nature, timing and accounting for restructuring charges, derivative assets and liabilities and the impact thereof; contingencies; litigation, administrative or arbitration proceedings; environmental compliance and changes in the regulatory environment; offerings, limitations on sales or offering of equity or debt securities, including asset sales and associated costs; and future working capital, costs, revenues, business opportunities, debt levels, cash flows, margins, taxes, earnings and growth. These statements are based on assumptions and assessments made by our management considering their experience and their perception of historical and current trends, current conditions, possible future developments, and other factors they believe to be appropriate. Forward-looking statements are not guarantees, representations or warranties and are subject to risks and uncertainties, many of which are unforeseeable and beyond our control and could cause actual results, developments, and business decisions to differ materially from those contemplated by such forward-looking statements. Some of those risks and uncertainties include the risk factors set forth in our filings with the SEC and the following: adverse effects of climate changes or natural disasters; adverse effects of global or regional pandemic disease spread or other crises; global economic and capital market uncertainties; the speculative nature of gold or mineral exploration, and lithium, nickel and cobalt recycling, including risks of diminishing quantities or grades of qualified resources; metal recycling, processing or mining activities; costs, hazards and uncertainties associated with precious metal based activities, including environmentally friendly and economically enhancing clean mining and processing technologies, precious metal exploration, resource development, economic feasibility assessment and cash generating mineral production; costs, hazards and uncertainties associated with metal recycling, processing or mining activities; contests over our title to properties; potential dilution to our stockholders from our stock issuances, recapitalization and balance sheet restructuring activities; potential inability to comply with applicable government regulations or law; adoption of or changes in legislation or regulations adversely affecting our businesses; permitting constraints or delays; ability to achieve the benefits of business opportunities that may be presented to, or pursued by, us, including those involving battery technology, quantum computing and advanced materials development, and development of cellulosic technology in bio-fuels and related carbon-based material production; ability to successfully identify, finance, complete and integrate acquisitions, joint ventures, strategic alliances, business combinations, asset sales, and investments that we may be party to in the future; changes in the United States or other monetary or fiscal policies or regulations; interruptions in our production capabilities due to capital constraints; equipment failures; fluctuation of prices for gold or certain other commodities (such as silver, zinc, lithium, nickel, cobalt, cyanide, water, diesel, gasoline and alternative fuels and electricity); changes in generally accepted accounting principles; adverse effects of war, mass shooting, terrorism and geopolitical events; potential inability to implement our business strategies; potential inability to grow revenues; potential inability to attract and retain key personnel; interruptions in delivery of critical supplies, equipment and raw materials due to credit or other limitations imposed by vendors; assertion of claims, lawsuits and proceedings against us; potential inability to satisfy debt and lease obligations; potential inability to maintain an effective system of internal controls over financial reporting; potential inability or failure to timely file periodic reports with the Securities and Exchange Commission; potential inability to list our securities on any securities exchange or market or maintain the listing of our securities; and work stoppages or other labor difficulties. Occurrence of such events or circumstances could have a material adverse effect on our business, financial condition, results of operations or cash flows, or the market price of our securities. All subsequent written and oral forward-looking statements by or attributable to us or persons acting on our behalf are expressly qualified in their entirety by these factors. Except as may be required by securities or other law, we undertake no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise.



Neither this press release nor any related calls or discussions constitutes an offer to sell, the solicitation of an offer to buy or a recommendation with respect to any securities of the Company, the fund, or any other issuer.



Contact information:



<figure class="wp-block-table"><table><tbody><tr><td>Comstock Inc. P.O. Box 1118 Virginia City, NV 89440 www.comstock.inc</td><td>Corrado De Gasperis Executive Chairman &amp; CEO Tel (775) 847-4755 degasperis@comstockinc.com</td><td>Zach Spencer Director of External Relations Tel (775) 847-5272 Ext.151 questions@comstockinc.com</td></tr></tbody></table></figure>

Research, News, and Market Data on LODE



VIRGINIA CITY, Nev., Dec. 01, 2022 (GLOBE NEWSWIRE) &#8212; Comstock Inc. (NYSE: LODE) (“Comstock” or the “Company”) today announced the publication of the initial technical report for the Company’s Dayton Consolidated Project. Behre Dolbear authored the independent, initial assessment of the Dayton Consolidated Project mineral resources, as of November 1, 2022, compliant with current SEC S-K 1300 guidelines. The full report is available on the Company’s website, at&nbsp;www.comstock.inc/investors.



The estimated mineral resource is constrained within an open pit economic shell based on a gold price of $1,800 per ounce and reported at a cutoff grade of 0.007 ounce gold per ton. The estimate includes Measured and Indicated resources containing 293,000 ounces of gold and 2,120,000 ounces of silver, plus an additional Inferred resource containing 90,000 ounces of gold and 480,000 ounces of silver.







The Dayton resource is located approximately one mile south of the Company’s Lucerne mining area, along State Route&nbsp;342 and State Route 341. It includes the historic Dayton, Alhambra, Metropolitan, and Kossuth mines. Additional Comstock exploration areas located northwest, southwest, and south of the Dayton Project include Oest, Amazon Extension of Oest, and Spring Valley, respectively.



The Dayton project has long been known for high grade assays, with gold assays as high as 2.95 ounces per ton, and silver assays as high as 6.68 ounces per ton. Drilling by Comstock has also encountered significant thicknesses of mineralization, including 135 feet averaging 0.218 ounces per ton Au and 0.685 ounces per ton Ag (hole D11-21), 145 feet averaging 0.056 ounces per ton Au and 0.352 ounces per ton Ag (hole D11-33), 50 feet averaging 0.030 ounces per ton Au and 1.072 ounces per ton Ag (hole D94-17), 295 feet averaging 0.027 ounces per ton Au and 0.087 ounces per ton Ag (hole D10-01), and 235 feet averaging 0.031 ounces per ton Au and 0.102 ounces per ton Ag (hole SV12-05).



The report reflects a newly developed geologic model based on highly detailed and methodical identification and correlation of structural and lithological controls for mineralization.



Behre Dolbear’s conclusions include,




The Dayton Project represents an early stage but well-explored, epithermal, precious metal deposit within an historic world-class mining district.



The geology of the project area, particularly in the Dayton resource area, is well described and understood through vigorous surface and underground mapping and drill hole logging.



Based upon drilling, continuity of the mineralized zone appears to be good.



The QP opines that potentially higher-grade mineralization may exist in previously un-drilled areas in the Dayton resource where northeast striking faults intersect.



The deposit is hosted in structurally prepared rocks within the southerly striking east dipping Silver City fault zone extension. Grades and extent of mineralization are enhanced where this fault zone is intersected by north-south, northwest, and northeast striking faults and in particular where N50°E faults intersect N75°E faults.



At Spring Valley, high-grade or bonanza-style mineralization may be present as much of the area is covered by post-mineral gravel and historic mining is minimal.




“These results confirm the quality and growth potential of our Dayton resource,” stated Corrado De Gasperis, Comstock’s Executive Chairman and CEO. “When combined with the results of the recent technical report published on our Lucerne resource, Comstock controls significant, district-wide mineral resources with outstanding potential for further gold and silver mineral resource growth.”



Comstock plans to develop the Dayton resource systemically, through the deployment of more advanced mineral discovery technologies and a series of phased drilling programs and engineering studies. A first phase of drilling, recommended by Behre Dolbear, includes 70 RC holes totaling 31,500 feet that will, among other objectives, test for high grade mineralization and step out exploration into Spring Valley.



About Behre DolbearBehre Dolbear is a one of the oldest mineral industry advisory firms in the world, continuously operating since 1911. Behre Dolbear authored the&nbsp;Technical Report Summary, Dayton Consolidated Project, Lyon County, Nevada&nbsp;as an independent third-party, following the United States Security and Exchange Commission’s mining rules under subpart 1300 of Regulation S-K.



About ComstockComstock (NYSE: LODE) innovates technologies that contribute to global decarbonization and circularity by efficiently converting under-utilized natural resources into renewable fuels and electrification products that contribute to balancing global uses and emissions of carbon. The Company intends to achieve exponential growth and extraordinary financial, natural, and social gains by building, owning, and operating a fleet of advanced carbon neutral extraction and refining facilities, by selling an array of complementary process solutions and related services, and by licensing selected technologies to qualified strategic partners. To learn more, please visit&nbsp;www.comstock.inc.



Forward-Looking Statements&nbsp;This press release and any related calls or discussions may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, are forward-looking statements. The words “believe,” “expect,” “anticipate,” “estimate,” “project,” “plan,” “should,” “intend,” “may,” “will,” “would,” “potential” and similar expressions identify forward-looking statements but are not the exclusive means of doing so. Forward-looking statements include statements about matters such as: future industry market conditions; future explorations or acquisitions; future changes in our exploration activities; future prices and sales of, and demand for, our products; land entitlements and uses; permits; production capacity and operations; operating and overhead costs; future capital expenditures and their impact on us; operational and management changes (including changes in the Board of Directors); changes in business strategies, planning and tactics; future employment and contributions of personnel, including consultants; future land sales; investments, acquisitions, joint ventures, strategic alliances, business combinations, operational, tax, financial and restructuring initiatives, including the nature, timing and accounting for restructuring charges, derivative assets and liabilities and the impact thereof; contingencies; litigation, administrative or arbitration proceedings; environmental compliance and changes in the regulatory environment; offerings, limitations on sales or offering of equity or debt securities, including asset sales and associated costs; and future working capital, costs, revenues, business opportunities, debt levels, cash flows, margins, taxes, earnings and growth. These statements are based on assumptions and assessments made by our management considering their experience and their perception of historical and current trends, current conditions, possible future developments, and other factors they believe to be appropriate. Forward-looking statements are not guarantees, representations or warranties and are subject to risks and uncertainties, many of which are unforeseeable and beyond our control and could cause actual results, developments, and business decisions to differ materially from those contemplated by such forward-looking statements. Some of those risks and uncertainties include the risk factors set forth in our filings with the SEC and the following: adverse effects of climate changes or natural disasters; adverse effects of global or regional pandemic disease spread or other crises; global economic and capital market uncertainties; the speculative nature of gold or mineral exploration, and lithium, nickel and cobalt recycling, including risks of diminishing quantities or grades of qualified resources; metal recycling, processing or mining activities; costs, hazards and uncertainties associated with precious metal based activities, including environmentally friendly and economically enhancing clean mining and processing technologies, precious metal exploration, resource development, economic feasibility assessment and cash generating mineral production; costs, hazards and uncertainties associated with metal recycling, processing or mining activities; contests over our title to properties; potential dilution to our stockholders from our stock issuances, recapitalization and balance sheet restructuring activities; potential inability to comply with applicable government regulations or law; adoption of or changes in legislation or regulations adversely affecting our businesses; permitting constraints or delays; ability to achieve the benefits of business opportunities that may be presented to, or pursued by, us, including those involving battery technology, quantum computing and advanced materials development, and development of cellulosic technology in bio-fuels and related carbon-based material production; ability to successfully identify, finance, complete and integrate acquisitions, joint ventures, strategic alliances, business combinations, asset sales, and investments that we may be party to in the future; changes in the United States or other monetary or fiscal policies or regulations; interruptions in our production capabilities due to capital constraints; equipment failures; fluctuation of prices for gold or certain other commodities (such as silver, zinc, lithium, nickel, cobalt, cyanide, water, diesel, gasoline and alternative fuels and electricity); changes in generally accepted accounting principles; adverse effects of war, mass shooting, terrorism and geopolitical events; potential inability to implement our business strategies; potential inability to grow revenues; potential inability to attract and retain key personnel; interruptions in delivery of critical supplies, equipment and raw materials due to credit or other limitations imposed by vendors; assertion of claims, lawsuits and proceedings against us; potential inability to satisfy debt and lease obligations; potential inability to maintain an effective system of internal controls over financial reporting; potential inability or failure to timely file periodic reports with the Securities and Exchange Commission; potential inability to list our securities on any securities exchange or market or maintain the listing of our securities; and work stoppages or other labor difficulties. Occurrence of such events or circumstances could have a material adverse effect on our business, financial condition, results of operations or cash flows, or the market price of our securities. All subsequent written and oral forward-looking statements by or attributable to us or persons acting on our behalf are expressly qualified in their entirety by these factors. Except as may be required by securities or other law, we undertake no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise.



Neither this press release nor any related calls or discussions constitutes an offer to sell, the solicitation of an offer to buy or a recommendation with respect to any securities of the Company, the fund, or any other issuer.



Contact information:



Comstock Inc.P.O. Box 1118Virginia City, NV 89440www.comstock.incCorrado De GasperisExecutive Chairman &amp; CEOTel (775) 847-4755degasperis@comstockinc.comZach SpencerDirector of External RelationsTel (775) 847-5272 Ext.151questions@comstockinc.com

Release - Comstock Announces Dayton Mineral Resource Report Significantly Expands Gold and Silver Resources

Comstock Inc.

LODE

Renewable Fuel

<figure class="wp-block-image"><img src="https://www.noblelinx.com/images/channelchek/research-teaser-header.jpg" alt=""/></figure>



 Thursday, December 01, 2022



Item 9 Labs Corp. (OTCQX: INLB) is a vertically integrated cannabis operator and dispensary franchisor delivering premium products from its large-scale cultivation and production facilities in the United States. The award-winning Item 9 Labs brand specializes in best-in-class products and user experience across several cannabis categories. The company also offers a unique dispensary franchise model through the national Unity Rd. retail brand. Easing barriers to entry, the franchise provides an opportunity for both new and existing dispensary owners to leverage the knowledge, resources, and ongoing support needed to thrive in their state compliantly and successfully. Item 9 Labs brings the best industry practices to markets nationwide through distinctive retail experience, cultivation capabilities, and product innovation. The veteran management team combines a diverse skill set with deep experience in the cannabis sector, franchising, and the capital markets to lead a new generation of public cannabis companies that provide transparency, consistency, and well-being. Headquartered in Arizona, the company is currently expanding its operations space by up to 640,000-plus square feet on its 50-acre site, one of the largest properties in Arizona zoned to grow and cultivate flower. For additional information, visit https://investors.item9labscorp.com/.



Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.



Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.



Refer to the full report for the price target, fundamental analysis, and rating.



New CEO.&nbsp;Yesterday, Item 9 Labs announced Mike Weinberger, the Company's Chief Franchise Officer, has assumed the CEO mantle, replacing Andrew Bowden. Given the upcoming transformational acquisition of Sessions Cannabis, we view the change in leadership as a positive for the Company.



Franchise Experience. As Item 9 Labs goes full bore in cannabis franchising, Mr. Weinberger's long background in the franchising industry will become even more valuable, in our opinion. A 20-plus year franchise industry veteran, Mr. Weinberger launched Item 9 Labs Corp.'s dispensary franchise, Unity Rd., in 2018 and grew the brand to more than 20 entrepreneurial groups driving development across 10 states before the sale of Unity Rd. to Item 9 Labs. Mr. Weinberger also led 500 unit Maui Wowi, a global coffee and smoothie franchise.



<h2> <a href="https://www.channelchek.com/research-reports/25427">Get the Full Report</a></h2>







Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).



*Analyst certification and important disclosures included in the full report.&nbsp;NOTE: investment decisions should not be based upon the content of this research summary.&nbsp;Proper due diligence is required before making any investment decision.&nbsp;

<figure class="wp-block-image"><img decoding="async" src="https://www.noblelinx.com/images/channelchek/research-teaser-header.jpg" alt=""/></figure>



 Thursday, December 01, 2022



Item 9 Labs Corp. (OTCQX: INLB) is a vertically integrated cannabis operator and dispensary franchisor delivering premium products from its large-scale cultivation and production facilities in the United States. The award-winning Item 9 Labs brand specializes in best-in-class products and user experience across several cannabis categories. The company also offers a unique dispensary franchise model through the national Unity Rd. retail brand. Easing barriers to entry, the franchise provides an opportunity for both new and existing dispensary owners to leverage the knowledge, resources, and ongoing support needed to thrive in their state compliantly and successfully. Item 9 Labs brings the best industry practices to markets nationwide through distinctive retail experience, cultivation capabilities, and product innovation. The veteran management team combines a diverse skill set with deep experience in the cannabis sector, franchising, and the capital markets to lead a new generation of public cannabis companies that provide transparency, consistency, and well-being. Headquartered in Arizona, the company is currently expanding its operations space by up to 640,000-plus square feet on its 50-acre site, one of the largest properties in Arizona zoned to grow and cultivate flower. For additional information, visit https://investors.item9labscorp.com/.



Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.



Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.



Refer to the full report for the price target, fundamental analysis, and rating.



New CEO.&nbsp;Yesterday, Item 9 Labs announced Mike Weinberger, the Company&#8217;s Chief Franchise Officer, has assumed the CEO mantle, replacing Andrew Bowden. Given the upcoming transformational acquisition of Sessions Cannabis, we view the change in leadership as a positive for the Company.



Franchise Experience. As Item 9 Labs goes full bore in cannabis franchising, Mr. Weinberger&#8217;s long background in the franchising industry will become even more valuable, in our opinion. A 20-plus year franchise industry veteran, Mr. Weinberger launched Item 9 Labs Corp.&#8217;s dispensary franchise, Unity Rd., in 2018 and grew the brand to more than 20 entrepreneurial groups driving development across 10 states before the sale of Unity Rd. to Item 9 Labs. Mr. Weinberger also led 500 unit Maui Wowi, a global coffee and smoothie franchise.



<h2> <a href="https://www.channelchek.com/research-reports/25427">Get the Full Report</a></h2>







Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).



*Analyst certification and important disclosures included in the full report.&nbsp;NOTE: investment decisions should not be based upon the content of this research summary.&nbsp;Proper due diligence is required before making any investment decision.&nbsp;

Thursday, December 01, 2022



Item 9 Labs Corp. (OTCQX: INLB) is a vertically integrated cannabis operator and dispensary franchisor delivering premium products from its large-scale cultivation and production facilities in the United States. The award-winning Item 9 Labs brand specializes in best-in-class products and user experience across several cannabis categories. The company also offers a unique dispensary franchise model through the national Unity Rd. retail brand. Easing barriers to entry, the franchise provides an opportunity for both new and existing dispensary owners to leverage the knowledge, resources, and ongoing support needed to thrive in their state compliantly and successfully. Item 9 Labs brings the best industry practices to markets nationwide through distinctive retail experience, cultivation capabilities, and product innovation. The veteran management team combines a diverse skill set with deep experience in the cannabis sector, franchising, and the capital markets to lead a new generation of public cannabis companies that provide transparency, consistency, and well-being. Headquartered in Arizona, the company is currently expanding its operations space by up to 640,000-plus square feet on its 50-acre site, one of the largest properties in Arizona zoned to grow and cultivate flower. For additional information, visit https://investors.item9labscorp.com/.



Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.



Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.



Refer to the full report for the price target, fundamental analysis, and rating.



New CEO.&nbsp;Yesterday, Item 9 Labs announced Mike Weinberger, the Company&#8217;s Chief Franchise Officer, has assumed the CEO mantle, replacing Andrew Bowden. Given the upcoming transformational acquisition of Sessions Cannabis, we view the change in leadership as a positive for the Company.



Franchise Experience. As Item 9 Labs goes full bore in cannabis franchising, Mr. Weinberger&#8217;s long background in the franchising industry will become even more valuable, in our opinion. A 20-plus year franchise industry veteran, Mr. Weinberger launched Item 9 Labs Corp.&#8217;s dispensary franchise, Unity Rd., in 2018 and grew the brand to more than 20 entrepreneurial groups driving development across 10 states before the sale of Unity Rd. to Item 9 Labs. Mr. Weinberger also led 500 unit Maui Wowi, a global coffee and smoothie franchise.



Get the Full Report







Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).



*Analyst certification and important disclosures included in the full report.&nbsp;NOTE: investment decisions should not be based upon the content of this research summary.&nbsp;Proper due diligence is required before making any investment decision.&nbsp;

Item 9 Labs (INLB) - A Management Change

Cannabis

Drug Manufacturers

Health

INLB

Item 9 Labs

<figure class="wp-block-image"><img src="https://www.noblelinx.com/images/channelchek/research-teaser-header.jpg" alt=""/></figure>



 Thursday, December 01, 2022



Garibaldi Resources Corp. is an active Canadian-based junior exploration company focused on creating shareholder value through discoveries and strategic development of its assets in some of the most prolific mining regions in British Columbia and Mexico.



Mark Reichman, Senior Research Analyst, Natural Resources, Noble Capital Markets, Inc.



Refer to the full report for the price target, fundamental analysis, and rating.



Private placement.&nbsp;Garibaldi&nbsp;announced a private placement to raise gross proceeds of up to C$4 million to advance its flagship E&amp;L nickel-copper-cobalt project and other British Columbia properties, along with funding working capital. The offering consists of the sale of up to 10 million flow-through units (FT) at a price of C$0.30 per FT Unit for gross proceeds of up to C$3 million, and 4 million non-flow-through-units (Unit) at a price of C$0.25 per unit for gross proceeds of up to C$1.0 million.&nbsp;Proceeds from the sale of FT Units will be used to fund exploration, while proceeds from the sale of Units will fund working capital needs. See the body of this note for offering details.



2022 drilling program.&nbsp;The 2022 drill program at E&amp;L tested targets from the 2021 Geotech deep penetrating Z-Axis Tipper Electromagnetic (ZTEM) survey. Of four holes drilled, two were successful, including Hole EL-22-97b, a deep hole which intersected two intervals of E&amp;L gabbro more than 200 meters down plunge from previous drilling and intersected nickel-bearing disseminated and semi-massive sulphide mineralization. The two successful drill holes are lined with polyvinyl chloride (PVC) and Garibaldi intends to conduct a geophysical borehole electromagnetic (BHEM) survey to better plan future drill holes.



<h2> <a href="https://www.channelchek.com/research-reports/25428">Get the Full Report</a></h2>







Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).



*Analyst certification and important disclosures included in the full report.&nbsp;NOTE: investment decisions should not be based upon the content of this research summary.&nbsp;Proper due diligence is required before making any investment decision.&nbsp;

<figure class="wp-block-image"><img decoding="async" src="https://www.noblelinx.com/images/channelchek/research-teaser-header.jpg" alt=""/></figure>



 Thursday, December 01, 2022



Garibaldi Resources Corp. is an active Canadian-based junior exploration company focused on creating shareholder value through discoveries and strategic development of its assets in some of the most prolific mining regions in British Columbia and Mexico.



Mark Reichman, Senior Research Analyst, Natural Resources, Noble Capital Markets, Inc.



Refer to the full report for the price target, fundamental analysis, and rating.



Private placement.&nbsp;Garibaldi&nbsp;announced a private placement to raise gross proceeds of up to C$4 million to advance its flagship E&amp;L nickel-copper-cobalt project and other British Columbia properties, along with funding working capital. The offering consists of the sale of up to 10 million flow-through units (FT) at a price of C$0.30 per FT Unit for gross proceeds of up to C$3 million, and 4 million non-flow-through-units (Unit) at a price of C$0.25 per unit for gross proceeds of up to C$1.0 million.&nbsp;Proceeds from the sale of FT Units will be used to fund exploration, while proceeds from the sale of Units will fund working capital needs. See the body of this note for offering details.



2022 drilling program.&nbsp;The 2022 drill program at E&amp;L tested targets from the 2021 Geotech deep penetrating Z-Axis Tipper Electromagnetic (ZTEM) survey. Of four holes drilled, two were successful, including Hole EL-22-97b, a deep hole which intersected two intervals of E&amp;L gabbro more than 200 meters down plunge from previous drilling and intersected nickel-bearing disseminated and semi-massive sulphide mineralization. The two successful drill holes are lined with polyvinyl chloride (PVC) and Garibaldi intends to conduct a geophysical borehole electromagnetic (BHEM) survey to better plan future drill holes.



<h2> <a href="https://www.channelchek.com/research-reports/25428">Get the Full Report</a></h2>







Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).



*Analyst certification and important disclosures included in the full report.&nbsp;NOTE: investment decisions should not be based upon the content of this research summary.&nbsp;Proper due diligence is required before making any investment decision.&nbsp;

Thursday, December 01, 2022



Garibaldi Resources Corp. is an active Canadian-based junior exploration company focused on creating shareholder value through discoveries and strategic development of its assets in some of the most prolific mining regions in British Columbia and Mexico.



Mark Reichman, Senior Research Analyst, Natural Resources, Noble Capital Markets, Inc.



Refer to the full report for the price target, fundamental analysis, and rating.



Private placement.&nbsp;Garibaldi&nbsp;announced a private placement to raise gross proceeds of up to C$4 million to advance its flagship E&amp;L nickel-copper-cobalt project and other British Columbia properties, along with funding working capital. The offering consists of the sale of up to 10 million flow-through units (FT) at a price of C$0.30 per FT Unit for gross proceeds of up to C$3 million, and 4 million non-flow-through-units (Unit) at a price of C$0.25 per unit for gross proceeds of up to C$1.0 million.&nbsp;Proceeds from the sale of FT Units will be used to fund exploration, while proceeds from the sale of Units will fund working capital needs. See the body of this note for offering details.



2022 drilling program.&nbsp;The 2022 drill program at E&amp;L tested targets from the 2021 Geotech deep penetrating Z-Axis Tipper Electromagnetic (ZTEM) survey. Of four holes drilled, two were successful, including Hole EL-22-97b, a deep hole which intersected two intervals of E&amp;L gabbro more than 200 meters down plunge from previous drilling and intersected nickel-bearing disseminated and semi-massive sulphide mineralization. The two successful drill holes are lined with polyvinyl chloride (PVC) and Garibaldi intends to conduct a geophysical borehole electromagnetic (BHEM) survey to better plan future drill holes.



Get the Full Report







Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).



*Analyst certification and important disclosures included in the full report.&nbsp;NOTE: investment decisions should not be based upon the content of this research summary.&nbsp;Proper due diligence is required before making any investment decision.&nbsp;

Garibaldi Resources Corp. (GGIFF) - Looking Ahead to 2023

Basic Materials

Garibaldi Resources Corp.

GGIFF

Mining

<figure class="wp-block-image"><img src="https://www.noblelinx.com/images/channelchek/research-teaser-header.jpg" alt=""/></figure>



 Thursday, December 01, 2022



Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.



Patrick McCann, Research Associate, Noble Capital Markets, Inc.



Refer to the full report for the price target, fundamental analysis, and rating.



Initiation.&nbsp;We are initiating research coverage of Commercial Vehicle Group, Inc. (CVG) with an outperform rating and a $10.00 price target. CVG is in the midst of a business transformation&nbsp;to drive top line revenue and overall margin improvements, with a goal of doubling revenue and increasing adjusted operating margin by 300 basis points by the 2025-2027 time frame.



Attractive End Markets. Long-term prospects for CVG's key end markets are attractive. Demand for class 8 trucks exceeds supply and, with an aging fleet, is likely to continue. The ongoing switch to electric vehicles is opening a massive opportunity for CVG. And while the warehouse automation vertical is currently challenging, longer term we expect to see significant growth. 



<h2> <a href="https://www.channelchek.com/research-reports/25248">Get the Full Report</a></h2>







Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).



*Analyst certification and important disclosures included in the full report.&nbsp;NOTE: investment decisions should not be based upon the content of this research summary.&nbsp;Proper due diligence is required before making any investment decision.&nbsp;

<figure class="wp-block-image"><img decoding="async" src="https://www.noblelinx.com/images/channelchek/research-teaser-header.jpg" alt=""/></figure>



 Thursday, December 01, 2022



Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.



Patrick McCann, Research Associate, Noble Capital Markets, Inc.



Refer to the full report for the price target, fundamental analysis, and rating.



Initiation.&nbsp;We are initiating research coverage of Commercial Vehicle Group, Inc. (CVG) with an outperform rating and a $10.00 price target. CVG is in the midst of a business transformation&nbsp;to drive top line revenue and overall margin improvements, with a goal of doubling revenue and increasing adjusted operating margin by 300 basis points by the 2025-2027 time frame.



Attractive End Markets. Long-term prospects for CVG&#8217;s key end markets are attractive. Demand for class 8 trucks exceeds supply and, with an aging fleet, is likely to continue. The ongoing switch to electric vehicles is opening a massive opportunity for CVG. And while the warehouse automation vertical is currently challenging, longer term we expect to see significant growth. 



<h2> <a href="https://www.channelchek.com/research-reports/25248">Get the Full Report</a></h2>







Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).



*Analyst certification and important disclosures included in the full report.&nbsp;NOTE: investment decisions should not be based upon the content of this research summary.&nbsp;Proper due diligence is required before making any investment decision.&nbsp;

Thursday, December 01, 2022



Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.



Patrick McCann, Research Associate, Noble Capital Markets, Inc.



Refer to the full report for the price target, fundamental analysis, and rating.



Initiation.&nbsp;We are initiating research coverage of Commercial Vehicle Group, Inc. (CVG) with an outperform rating and a $10.00 price target. CVG is in the midst of a business transformation&nbsp;to drive top line revenue and overall margin improvements, with a goal of doubling revenue and increasing adjusted operating margin by 300 basis points by the 2025-2027 time frame.



Attractive End Markets. Long-term prospects for CVG&#8217;s key end markets are attractive. Demand for class 8 trucks exceeds supply and, with an aging fleet, is likely to continue. The ongoing switch to electric vehicles is opening a massive opportunity for CVG. And while the warehouse automation vertical is currently challenging, longer term we expect to see significant growth. 



Get the Full Report







Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).



*Analyst certification and important disclosures included in the full report.&nbsp;NOTE: investment decisions should not be based upon the content of this research summary.&nbsp;Proper due diligence is required before making any investment decision.&nbsp;

Commercial Vehicle Group, Inc. (CVGI) - A Business Transformation

Auto Parts

Commercial Vehicle Group

Consumer

Consumer Cyclical

CVGI

<figure class="wp-block-image"><img src="https://www.noblelinx.com/images/channelchek/research-teaser-header.jpg" alt=""/></figure>



 Thursday, December 01, 2022



Baudax Bio is a pharmaceutical company focused on innovative products for acute care settings. ANJESO is the first and only 24-hour, intravenous (IV) COX-2 preferential non-steroidal anti-inflammatory (NSAID) for the management of moderate to severe pain. In addition to ANJESO, Baudax Bio has a pipeline of other innovative pharmaceutical assets including two novel neuromuscular blocking agents (NMBs) and a proprietary chemical reversal agent specific to these NMBs. For more information, please visit www.baudaxbio.com.



Gregory Aurand, Senior Research Analyst, Healthcare Services &amp; Medical Devices, Noble Capital Markets, Inc.



Refer to the full report for the price target, fundamental analysis, and rating.



Stock split approved at November 3, 2022 shareholder meeting. Shareholders of record September 29, 2022, approved the 1-for-40 stock split. The stock split will become effective for December 1, 2022, Nasdaq trading. The Company's common stock will also commence trading under a new CUSIP number (07160F404).



Curing the deficiency.&nbsp;&nbsp;Baudax Bio received Nasdaq notice that the minimum $1.00 bid price requirement was not being met and had until January 2, 2023, to cure the issue, unless they sought to obtain an additional 180 days to regain compliance.&nbsp; The reverse split should bring the Company into listing compliance.



<h2> <a href="https://www.channelchek.com/research-reports/25429">Get the Full Report</a></h2>







Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).



*Analyst certification and important disclosures included in the full report.&nbsp;NOTE: investment decisions should not be based upon the content of this research summary.&nbsp;Proper due diligence is required before making any investment decision.&nbsp;

<figure class="wp-block-image"><img decoding="async" src="https://www.noblelinx.com/images/channelchek/research-teaser-header.jpg" alt=""/></figure>



 Thursday, December 01, 2022



Baudax Bio is a pharmaceutical company focused on innovative products for acute care settings. ANJESO is the first and only 24-hour, intravenous (IV) COX-2 preferential non-steroidal anti-inflammatory (NSAID) for the management of moderate to severe pain. In addition to ANJESO, Baudax Bio has a pipeline of other innovative pharmaceutical assets including two novel neuromuscular blocking agents (NMBs) and a proprietary chemical reversal agent specific to these NMBs. For more information, please visit www.baudaxbio.com.



Gregory Aurand, Senior Research Analyst, Healthcare Services &amp; Medical Devices, Noble Capital Markets, Inc.



Refer to the full report for the price target, fundamental analysis, and rating.



Stock split approved at November 3, 2022 shareholder meeting. Shareholders of record September 29, 2022, approved the 1-for-40 stock split. The stock split will become effective for December 1, 2022, Nasdaq trading. The Company&#8217;s common stock will also commence trading under a new CUSIP number (07160F404).



Curing the deficiency.&nbsp;&nbsp;Baudax Bio received Nasdaq notice that the minimum $1.00 bid price requirement was not being met and had until January 2, 2023, to cure the issue, unless they sought to obtain an additional 180 days to regain compliance.&nbsp; The reverse split should bring the Company into listing compliance.



<h2> <a href="https://www.channelchek.com/research-reports/25429">Get the Full Report</a></h2>







Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).



*Analyst certification and important disclosures included in the full report.&nbsp;NOTE: investment decisions should not be based upon the content of this research summary.&nbsp;Proper due diligence is required before making any investment decision.&nbsp;

Thursday, December 01, 2022



Baudax Bio is a pharmaceutical company focused on innovative products for acute care settings. ANJESO is the first and only 24-hour, intravenous (IV) COX-2 preferential non-steroidal anti-inflammatory (NSAID) for the management of moderate to severe pain. In addition to ANJESO, Baudax Bio has a pipeline of other innovative pharmaceutical assets including two novel neuromuscular blocking agents (NMBs) and a proprietary chemical reversal agent specific to these NMBs. For more information, please visit www.baudaxbio.com.



Gregory Aurand, Senior Research Analyst, Healthcare Services &amp; Medical Devices, Noble Capital Markets, Inc.



Refer to the full report for the price target, fundamental analysis, and rating.



Stock split approved at November 3, 2022 shareholder meeting. Shareholders of record September 29, 2022, approved the 1-for-40 stock split. The stock split will become effective for December 1, 2022, Nasdaq trading. The Company&#8217;s common stock will also commence trading under a new CUSIP number (07160F404).



Curing the deficiency.&nbsp;&nbsp;Baudax Bio received Nasdaq notice that the minimum $1.00 bid price requirement was not being met and had until January 2, 2023, to cure the issue, unless they sought to obtain an additional 180 days to regain compliance.&nbsp; The reverse split should bring the Company into listing compliance.



Get the Full Report







Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.



This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).



*Analyst certification and important disclosures included in the full report.&nbsp;NOTE: investment decisions should not be based upon the content of this research summary.&nbsp;Proper due diligence is required before making any investment decision.&nbsp;